# CANLAB INTERNATIONAL - Growth Factors & Anabolic Peptides Library

**Category**: Muscle Building | Strength Enhancement | Hypertrophy | Performance | Fat-Free Mass Gain

---

## FRONTEND - Quick Reference Overview

### Category Summary
Anabolic and growth-promoting peptides that stimulate muscle protein synthesis, increase strength, and optimize body composition through GH axis stimulation, IGF-1 activation, or myostatin inhibition.

### Quick Reference Table

| Product | Price | Size | Evidence | Risk | Best For | Regulatory |
|---------|-------|------|----------|------|----------|-------------|
| IGF-1 LR3 | $150 | 1mg | B–C | Moderate–Higher | Muscle gain, strength | Research-only |
| ACE-031 | $160 | 1mg | B–C | Moderate | Muscle preservation, fat loss | Investigational |
| Follistatin 344 | $160 | 1mg | B–C | Moderate–Higher | Muscle growth, myostatin inhibition | Research-only |
| Sermorelin | $50 | 5mg | B–C | Moderate | GH axis stimulation, recovery | Off-label Rx |
| CJC-1295 (No DAC) | $95 | 5mg | B–C | Moderate | GH stimulation, muscle building | Research-only |
| CJC-1295 + Ipamorelin | $75 | 3–4.5mg | B–C | Moderate | Synergistic GH release | Research-only |
| Ipamorelin | $50 | 5mg | B–C | Moderate | GHRP activity, appetite/recovery | Research-only |
| Melanotan-1 | $40 | 10mg | D–E | Low–Moderate | Tanning, libido (secondary) | Research-only |
| Melanotan-2 | $35 | 10mg | D–E | Low–Moderate | Tanning, body composition | Research-only |
| PT-141 | $45 | 10mg | C–D | Low–Moderate | Sexual function, arousal | Research-only |
| Testagen | $50 | 20mg | D | Low–Moderate | Testosterone support (bioregulator) | Research-only |

---

## BACKEND - Full Product Entries (11-Section Template)

### IGF-1 LR3 Protocol

---

## Protocol Card (Top Summary)

**Protocol name**: IGF-1 LR3 Anabolic Protocol
**Category**: Body Composition | Muscle Growth | Strength Enhancement
**Status label**: Research-only / Investigational (banned in sports; Schedule III in some countries)
**Evidence grade**: B–C (Moderate human trials in GH-deficient populations; robust animal data)
**Risk tier**: Moderate–Higher
**Ideal candidate**: Experienced strength athletes, muscle-building goals, metabolic optimization, recovery from catabolic states
**Not a fit for**: Cancer history, diabetes (without intensive monitoring), teenagers, pregnancy, sedentary individuals

#### Quick outcomes (what patients usually want)
- **Primary goal**: 5–15 lbs lean mass gain, 10–20% strength increase, improved body composition
- **What you may notice first**: Increased strength, energy, appetite changes, pumps (3–7 days)
- **What takes longer**: Measurable lean mass gain, body composition shift, metabolic adaptation (2–4 weeks)
- **How we judge success**: Body composition (DEXA/BodPod), strength progression (training logs), fasting glucose stability

#### What this protocol includes
- **Core compound**: IGF-1 LR3 (30–100 mcg SC, 1–2x daily)
- **Synergy stack**: High carbs (4–6g/kg daily – ESSENTIAL), protein (1.2–1.8g/lb), creatine, magnesium, potassium, collagen peptides
- **Training pairing**: Hypertrophy block (high-volume, 6–12 reps, 3–5x/week), progressive overload mandatory
- **Monitoring**: Daily fasting glucose (>80 mg/dL critical), weekly strength logs, monthly body comp, joint pain tracking

#### Safety at a glance
- **Common side effects**: Hypoglycemia (DANGEROUS if not fed adequately), joint aches, carpal tunnel symptoms, fluid retention, headaches, numbness/tingling
- **Serious warnings**: Severe hypoglycemia risk (<70 mg/dL); growth signaling concern in cancer; joint/connective tissue stress; hypertension; cumulative side effects with other growth factors
- **Do NOT use if**: Cancer history, uncontrolled diabetes (fasting glucose >110 mg/dL), severe cardiac disease, teenagers with open growth plates, pregnancy
- **Use caution if**: Family cancer history, carpal tunnel syndrome, joint disease, poor dietary compliance, sedentary lifestyle

---

## 1) Patient Eligibility (Who this is for)

#### Best-fit profile
- **Goal + context**: Experienced lifters seeking significant muscle/strength gains; metabolic optimization; recovery from illness/catabolic state (muscle wasting)
- **Training status**: Actively training 3–5x/week (minimum); experienced with progressive overload; understand training periodization
- **History factors**: Able to consume high carbohydrate intake (4–6g/kg daily); willing to monitor fasting glucose daily; compliant with structured protocols; no cancer history; cardiovascular health stable

#### Not recommended / avoid
- **Pregnancy/breastfeeding**: Teratogenic risk unknown; avoid
- **Active cancer or cancer history**: Growth signaling (IGF-1 receptor activation) may theoretically promote tumor growth; absolute contraindication unless oncology-cleared
- **Uncontrolled diabetes**: Fasting glucose >110 mg/dL or HbA1c >6.5%; extreme hypoglycemia risk
- **Teenagers (<25 years) with open growth plates**: Risk of gigantism, disproportionate growth
- **Sedentary individuals**: Strength gain without trained musculoskeletal system increases injury risk

#### When we use caution
- **Cardiovascular risk**: Hypertension (>140/90); monitor BP monthly; IGF-1 can transiently elevate BP in some users
- **Family history of cancer**: Not absolute contraindication but elevated concern; discuss with oncology; monitor closely
- **Carpal tunnel syndrome**: Pre-existing nerve compression may worsen; monitor symptoms weekly
- **Joint disease or instability**: Rapid strength gain can outpace connective tissue adaptation; risk of injury
- **Poor dietary compliance**: Unable to consistently consume 4–6g/kg carbs daily = dangerous hypoglycemia risk

---

## 2) Expected Benefits (Ranked)

| Benefit | Who It Helps | Evidence Note | How We Measure It |
|---------|-------------|---------------|-------------------|
| **Lean muscle gain** | Athletes, hypertrophy trainees, sarcopenia patients | B–C (RCTs in GH-deficient; anecdotal in healthy athletes) | Body composition (DEXA/BodPod), scale weight (+1–2 lbs/week lean if training optimal) |
| **Strength improvement** | Strength athletes, powerlifters, weight lifters | B–C (training/dose-dependent; 10–20% gains typical) | Training logs (squat, bench, deadlift 1RM or 5RM), progressive load increases |
| **Metabolic flexibility** | Endurance athletes, fat-loss phases (with adequate protein) | D (mechanistic; limited human data) | Fasting glucose, HbA1c, subjective energy during training |
| **Joint recovery (paradox)** | Joint-stressed athletes (caution – double-edged sword) | C–D (animal data positive; human risk/benefit unclear) | Joint pain scale (0–10), ROM, functional capacity; monitor for worsening |
| **Insulin sensitivity (paradoxical)** | Can improve or impair depending on dose/diet | D (mechanistic only; paradoxical effects) | Fasting glucose (must stay >80 mg/dL), HOMA-IR if available |

#### Secondary benefits (optional)
- **Improved workout recovery** → Evidence: Anecdotal; athletes report faster bounce-back between sessions
- **Body recomposition during deficit** → Evidence: D (mechanistic; spares lean mass if protein adequate)

---

## 3) Downsides / Tradeoffs (Honest)

#### Common drawbacks
- **High side-effect burden**: Hypoglycemia (most dangerous), joint pain (common), carpal tunnel (20–30% users), fluid retention, headaches
- **Cost/effort**: $150–300 per vial; requires 1–2 daily injections for 8–12 weeks; expensive per cycle
- **Results variability**: Highly individual; some gain 15 lbs lean, others 5 lbs; glucose sensitivity varies dramatically

#### What it does NOT do well
- **Myth busting**: Does NOT directly increase testosterone (works via IGF-1 receptor, not androgen); does NOT cause joint inflammation (mechanical stress from rapid strength gain); does NOT increase metabolic rate directly (anabolic, not thermogenic)
- **Unrealistic expectations**: Won't build muscle without training stimulus; requires HIGH volume training (15+ sets/muscle/week); requires adequate protein/carbs (non-negotiable)

#### Most common reasons it "doesn't work"
- **Training mismatch**: Low training volume (<10 sets/muscle/week); inadequate progressive overload; too much cardio (catabolic)
- **Sleep deficit**: <7 hours nightly; IGF-1 requires deep sleep for GH synergy
- **Diet nonadherence**: Insufficient carbs (<4g/kg) = hypoglycemia risk + poor gains; insufficient protein (<1.2g/lb) = muscle wasting
- **Wrong candidate profile**: Beginners (should focus on training optimization first); sedentary individuals (injury risk)
- **Stack interference**: Excessive cardio, caloric deficit, cortisol-elevating stressors negate anabolic effects

---

## 4) Mechanism of Action (Simple → Technical)

#### Plain English
IGF-1 LR3 is a modified version of insulin-like growth factor that lasts longer in your body (days instead of minutes). It binds to receptors on muscle cells, triggering a growth signal that increases protein production (building blocks of muscle) and decreases protein breakdown. It also helps cells absorb glucose (sugar) from your blood for energy, which is why you need to eat enough carbs to avoid dangerous low blood sugar. Think of it as telling your muscles "grow now" while also making them hungry for fuel.

#### Key pathways (for advanced readers)
- **IGF-1 receptor activation → mTOR pathway upregulation**: Primary anabolic signal; increases ribosomal protein synthesis, myofibrillar growth
- **PI3K/Akt upregulation**: Inhibits FOXO (prevents protein breakdown via ubiquitin-proteasome pathway); enhances glucose uptake via GLUT4 translocation
- **GLUT4 translocation**: Insulin-independent glucose uptake; increases cellular energy availability for anabolism
- **Myostatin downregulation**: Reduces negative regulator of muscle growth; permits hypertrophy beyond normal genetic limits
- **Protein breakdown inhibition**: Suppresses ubiquitin-proteasome degradation pathway; preserves lean mass during catabolic states

#### What's uncertain / still emerging
- **Long-term safety in healthy athletes**: Most human trials <16 weeks; effects of prolonged/repeated cycles unknown
- **Cancer risk quantification**: Theoretical concern based on IGF-1 receptor signaling in tumor models; no definitive human cancer link proven but mechanistic plausibility high
- **Optimal dosing in humans**: Animal-to-human extrapolation not validated; individual glucose sensitivity varies dramatically
- **Interaction with endogenous IGF-1**: Does exogenous IGF-1 LR3 suppress natural production? Rebound effects post-cycle? Unclear.

---

## 5) The Protocol Itself (Public-Safe)

#### Core compound plan (clinic-guided)
- **Form**: Injectable (subcutaneous into fatty tissue – abdomen, thigh, love handles)
- **Schedule style**: Daily or 5–6 days per week; 1–2 injections daily (split AM/PM or post-workout)
- **Typical duration**: 8–12 weeks (longer cycles increase side-effect burden; diminishing returns after 12 weeks)
- **Adjustment logic**: Start low (30 mcg once daily), titrate up based on fasting glucose (must stay >80 mg/dL), strength response, and side-effect tolerance; increase by 10–20 mcg if minimal response after 2 weeks; decrease if hypoglycemic episodes occur; stop if fasting glucose trends <75 mg/dL or severe joint pain/carpal tunnel

**Public note**: Protocol specifics are individualized by a licensed clinician and may differ based on medical history, body weight, glucose sensitivity, and goals. IGF-1 LR3 is available only through research suppliers; verify purity (>98%), concentration accuracy, refrigeration integrity (2–8°C), and batch testing. Counterfeit products are extremely common.

---

## 6) Synergy Stack (Make it "Plug-and-Play")

#### Tier 1 — Foundational (NON-NEGOTIABLE for IGF-1 use)
- **Carbohydrates** (4–6g/kg body weight daily): **CRITICAL** to prevent life-threatening hypoglycemia; consume every 3–4 hours; never skip meals while on IGF-1
- **Protein** (1.2–1.8g/lb body weight): Muscle building substrate; emphasize high-quality sources (whey, lean meats, eggs)
- **Creatine** (5g daily): ATP regeneration, strength, cellular hydration; synergistic with IGF-1 for muscle growth
- **Magnesium glycinate** (400–500mg daily): Muscle function, recovery, glucose regulation (cofactor in 300+ enzymes)
- **Potassium** (2500–3500mg daily from food): Cellular signaling, muscle cramps prevention, electrolyte balance during high training volume
- **Sodium** (2000–3000mg daily from food): Electrolyte balance, cellular function, nutrient delivery
- **Sleep** (8–9 hours nightly): GH release during deep sleep synergizes with IGF-1; sleep deficit negates benefits

#### Tier 2 — Goal-specific add-ons (highly recommended)

**Strength / hypertrophy**
- **Beta-alanine** (3–5g daily divided doses): Buffering, muscular endurance in hypertrophy rep ranges (6–12 reps)
- **Taurine** (2–3g daily): Cell osmolarity, muscle function, reduces cramping during high-volume training
- **Zinc/Magnesium (ZMA)** (evening dose): Testosterone production support (if male), sleep quality, immune function

**Joint adaptation (essential given rapid strength gains)**
- **Collagen hydrolysate** (10–15g daily): Connective tissue support; joints must adapt to rapid strength increase
- **Vitamin C** (500–1000mg with meals): Collagen synthesis cofactor; antioxidant support during high training stress
- **Glucosamine/Chondroitin** (1500mg/1200mg daily): Joint health support (evidence mixed but low risk)

**Metabolic support**
- **L-Carnitine** (1–2g daily): Mitochondrial function, fat oxidation, cellular energy during caloric surplus
- **Alpha-lipoic acid** (300–600mg daily): Insulin sensitivity support, glucose disposal, antioxidant

#### Tier 3 — Advanced stack (ONLY if expert-level)
- **Testosterone** (if male, clinician-prescribed): Synergistic anabolic pathways; exponentially increases muscle gain but also side effects and complexity
- **Growth Hormone** (clinician-prescribed): Triple-growth-axis (GH + IGF-1 + Testosterone) = extreme results but extreme risk and cost
- **Sermorelin/Ipamorelin**: GHRH/GHRP support for endogenous GH stimulation; safer than exogenous GH

#### "Avoid combining" (CRITICAL safety)
- **Avoid pairing with**: Insulin + IGF-1 LR3 (extreme hypoglycemia risk <50 mg/dL; life-threatening; requires expert medical supervision)
- **Why**: Both drive glucose into cells; cumulative effect can cause sudden severe hypoglycemia (seizures, loss of consciousness, death)
- **Avoid pairing with**: Multiple high-dose growth peptides (IGF-1 LR3 + ACE-031 + Follistatin 344 all at maximum dose)
- **Why**: Synergistic cancer signaling risk; cumulative joint stress; cost without proven additive benefit; unknown interaction safety

---

## 7) Training Protocol Pairing (How to Make It Work)

#### Recommended emphasis (choose 1–2)
- **Hypertrophy block** (6–12 reps, 3–4 sets, primary focus)
- **Strength block** (high-volume variant, 15+ sets/muscle/week)

#### The minimal effective training plan
- **Strength**: 3–5 days/week; heavy compound lifts (squats, deadlifts, bench press, rows, overhead press); 3–4 sets × 6–12 reps; progressive overload MANDATORY (add weight/reps weekly); adequate rest (2–3 min between sets)
- **Zone 2**: 0–2 days/week (optional; low-priority; excessive cardio counterproductive for muscle gain)
- **Mobility/rehab**: 10–15 min daily (dynamic warm-up, ROM work); prioritize joint health given rapid strength gain

#### What to avoid (most common mistakes)
- **Excessive endurance work**: >150 min/week cardio is counterproductive (catabolic, interferes with recovery)
- **Training to failure on first exercises**: Save failure sets for last exercises; CNS fatigue limits volume if failing early
- **Rapid deloads**: IGF-1 thrives on volume; maintain training intensity; only deload if joint pain severe
- **Max testing during cycle**: Avoid 1RM attempts mid-cycle (injury risk; connective tissue lags strength gains); test at cycle end

#### Success pattern
- **"Progressive overload every session"**: Add 2.5–5 lbs to compound lifts weekly; increase reps if weight can't progress; volume accumulation (total sets × reps × weight) should increase week-over-week

---

## 8) Contraindications, Warnings, Interactions

#### Absolute contraindications (Do NOT use)
- Active cancer or cancer history (unless oncology-cleared with signed informed consent; significant growth signaling risk)
- Uncontrolled diabetes (fasting glucose >110 mg/dL) or pre-diabetes with elevated HbA1c (>6.0%)
- Severe cardiac disease or uncontrolled hypertension (>160/100)
- Teenagers with open growth plates (<25 years typically; verify via X-ray if uncertain)
- Pregnancy or breastfeeding (teratogenic risk unknown)
- Severe joint disease or instability (rapid strength gain will exacerbate; high injury risk)

#### Relative contraindications (Caution – may proceed with intensive monitoring)
- Family history of cancer (not absolute; elevated concern; discuss risks; monitor closely)
- Carpal tunnel syndrome or nerve compression (IGF-1 can worsen; monitor symptoms weekly)
- Mild-moderate hypertension (130–159 / 85–99; monitor BP weekly; may worsen)
- Poor dietary compliance (unable to consistently consume 4–6g/kg carbs = unacceptable hypoglycemia risk)
- Sedentary lifestyle or training beginner (strength gain without musculoskeletal conditioning = injury)

#### Common side effects
- Hypoglycemia (20–40% users if carbs inadequate; symptoms: shakiness, sweating, confusion, tachycardia, blurred vision)
- Joint aches (30–50% users; mechanical stress from rapid strength gain)
- Carpal tunnel symptoms (20–30% users; numbness, tingling in hands, worse at night)
- Fluid retention (mild; transient; typically resolves after 2–3 weeks)
- Headaches (10–20% users; mild; usually first week)

#### Serious warnings (seek immediate care)
- Severe hypoglycemia (<60 mg/dL; symptoms: confusion, loss of consciousness, seizures) → Emergency glucose administration (juice, candy, glucagon if available)
- Severe joint pain limiting function → Stop IGF-1 immediately; imaging (MRI) if pain persists
- Chest pain or cardiac symptoms → Discontinue; seek emergency care (rule out cardiac event)
- Vision changes (blurred vision persisting beyond hypoglycemic episode) → Ophthalmology consult
- Severe carpal tunnel (hand weakness, inability to grip) → Neurology consult; may require surgery

#### Interaction considerations
- **Medications**: Potentiates insulin/oral hypoglycemics (metformin, sulfonylureas) → extreme hypoglycemia risk; do NOT combine without endocrinology oversight
- **Supplements**: Synergistic with other growth factors (GH, testosterone) → exponential side effects and cancer risk
- **Stack complexity warning**: Combining IGF-1 + insulin + GH + testosterone = professional bodybuilder-level complexity; requires expert medical supervision, frequent labs, and acceptance of significant health risks

#### Quality + sourcing safety note (CRITICAL)
**IGF-1 LR3 is only available from research suppliers.** Quality and dosing variability is EXTREME and dangerous. The FDA has warned about unapproved products falsely labeled "for research purposes" being sold for human use without proper oversight, purity testing, or sterility assurance. Counterfeit products are the NORM, not the exception. Many contain:
- Wrong concentration (overdose/underdose by 50–200%)
- Bacterial contamination (endotoxins causing infection, sepsis)
- Incorrect molecular form (degraded peptide, inactive)
- No refrigeration during shipping (peptide degraded, inactive)

**Verification steps (MANDATORY)**:
- Request Certificate of Analysis (CoA) showing >98% purity via HPLC
- Verify batch/lot numbers match product label
- Confirm proper refrigeration upon arrival (2–8°C; vial cold to touch)
- Test product if possible (send sample to third-party lab; expensive but prudent)

---

## 9) Monitoring Plan (Symptoms + Optional Labs)

#### Daily/weekly self-tracking (MANDATORY for safety)
- **Fasting blood glucose** (EVERY MORNING with home meter): MUST stay >80 mg/dL; if <75 mg/dL, reduce dose immediately
- **Workout strength/performance** (training log every session): Track lifts, expect 10–20% strength gains over 8–12 weeks
- **Body weight** (weekly, same time/day): Expect 1–2 lbs/week gain if training/eating optimal; if >3 lbs/week, likely water/fat not muscle
- **Joint pain** (0–10 scale, track daily): Note location, severity, function limitation; reduce training volume if >6/10
- **Carpal tunnel symptoms** (daily check): Numbness, tingling, hand weakness; worse at night typical; severe = stop IGF-1
- **Energy, appetite, mood** (daily log): Indirect recovery markers; appetite should increase (sign of anabolism)
- **Sleep quality** (0–10 scale nightly): 8–9 hours mandatory; disrupted sleep negates benefits
- **Injection site reaction** (after each injection): Mild redness normal; expanding warmth/swelling = infection risk

#### Clinician check-ins
- **Week 1–2**: Check injection technique, glucose monitoring compliance, initial tolerance, diet adequacy (carbs/protein targets met)
- **Week 4**: Evaluate strength response (10%+ gain expected), body composition trend, glucose stability, side-effect burden
- **Week 8–12**: Reassess need for continuation; cycle off at 12 weeks maximum; assess joint health, glucose stability, lipid panel

#### Optional labs (HIGHLY RECOMMENDED despite "optional" label)
- **Baseline (Week 0)**: Fasting glucose, HbA1c, lipid panel (total cholesterol, LDL, HDL, triglycerides), liver function (AST, ALT), kidney function (creatinine, BUN), testosterone (if male), blood pressure
- **Mid-protocol (Week 4–6)**: Fasting glucose, liver function (if on higher doses or multiple compounds), blood pressure
- **End-protocol (Week 8–12)**: Full repeat of baseline panel (assess recovery, lipid changes, glucose adaptation)
- **IGF-1 level** (optional; not required but helpful): Normal ~100–250 ng/mL; target 250–400 ng/mL during protocol (supraphysiological but within functional range)
- **Body composition** (DEXA or BodPod): Baseline, Week 8, Week 12 (gold standard for tracking lean mass gain vs. fat/water)

---

## 10) Stop / Pause / Escalation Criteria (Safety Rules)

#### Stop immediately and contact clinician if:
- **Severe hypoglycemia** (<60 mg/dL or symptoms of confusion, loss of consciousness, seizures) → Emergency glucose, glucagon if available, call 911 if unconscious
- **Severe joint pain** (>8/10, limiting daily function, unable to train) → Stop IGF-1; imaging (MRI) to rule out tendon rupture or severe damage
- **Chest pain, cardiac symptoms** (tachycardia, arrhythmias, shortness of breath) → Discontinue immediately; seek emergency care
- **Vision changes persisting** (blurred vision not resolved after glucose normalization) → Ophthalmology consult (rule out retinal issues)
- **Severe carpal tunnel** (hand weakness, inability to grip objects, constant numbness) → Stop IGF-1; neurology consult; may require surgical release

#### Pause and reassess if:
- **Fasting glucose trending <80 mg/dL** (even if asymptomatic) → Reduce dose by 25–50%; increase carb intake; recheck glucose daily
- **Joint pain >6/10 but tolerable** → Deload training volume by 30%; reduce IGF-1 dose; add collagen peptides/joint support; reassess weekly
- **Side effects persist beyond 4 weeks** (headaches, fluid retention, GI upset) → Consider dose reduction or discontinuation; may be intolerance
- **No strength/muscle gain after 4 weeks** (if diet/training optimal) → Verify product authenticity (may be counterfeit/degraded); consider discontinuation

#### Continue if:
- **Fasting glucose stable** (>80 mg/dL consistently; no hypoglycemic episodes)
- **Strength increasing progressively** (10–20% over 8 weeks; measurable weekly gains)
- **Body composition improving** (scale weight +1–2 lbs/week; visual muscle fullness; DEXA confirms lean mass gain)
- **Tolerating injections well** (minimal site reactions, manageable side effects)
- **Joint pain manageable** (<5/10; not limiting training; improving with collagen support)

---

## 11) Protocol Variants (A/B/C Options)

#### Option A — Minimalist (NOT RECOMMENDED for IGF-1 LR3)
**Note**: IGF-1 LR3 is a high-risk compound; minimalist approach not advisable due to hypoglycemia danger and monitoring intensity required. If cost/effort is barrier, consider alternative peptides (Sermorelin, BPC-157, etc.).

#### Option B — Performance (Recommended for most users)
**Who**: Experienced lifters, metabolic optimization, willing to invest in monitoring
**Core**:
- IGF-1 LR3 (50 mcg SC once daily or split AM/PM)
- Carbs (5g/kg daily), Protein (1.4g/lb), Creatine (5g), Magnesium (400mg), Potassium (adequate from food)
- Hypertrophy training (3–5x/week, progressive overload)
- Daily fasting glucose monitoring (home meter), weekly training logs, monthly body comp
- Collagen peptides (10g daily), Vitamin C (1g daily)
- Baseline + Week 8 labs (glucose, lipids, liver/kidney)

#### Option C — Advanced (Clinician-gated, expert-level)
**Who**: High-level athletes, competitive bodybuilding, comprehensive optimization, accept significant health risks
**Core**:
- IGF-1 LR3 (75–100 mcg SC, split AM/PM dosing)
- Full Tier 1 & 2 supplement stack (all micronutrients optimized)
- Testosterone (if male, clinician-prescribed) or Sermorelin (GH axis support)
- Hypertrophy training (5–6x/week, very high volume)
- Daily fasting glucose + weekly fasted labs (if accessible), bi-weekly clinician reviews
- Monthly body composition (DEXA), baseline + Week 4 + Week 8 + Week 12 labs (comprehensive panel)
- Advanced monitoring: Blood pressure daily, HRV tracking, sleep tracking (Oura/Whoop)

---

## 12) Education & Expectations (What patients should know)

#### What this is meant to do
- Amplify muscle protein synthesis and reduce breakdown in individuals with optimized training stimulus
- Support lean mass gain during caloric surplus with adequate protein/carb intake
- Enhance strength progression when combined with progressive overload training

#### What it can't replace
- **Sleep**: IGF-1 ineffective if <7 hours nightly; requires 8–9 hours for optimal results
- **Training consistency**: Peptide amplifies training stimulus; zero stimulus = zero benefit
- **Nutrition fundamentals**: Requires HIGH carb intake (4–6g/kg daily) + HIGH protein (1.2–1.8g/lb); non-negotiable for safety and efficacy
- **Progressive overload**: Must increase training load weekly; static training = minimal benefit

#### Realistic timelines
- **Early changes** (3–7 days): Increased strength in gym, improved pumps, appetite increase, energy boost
- **Meaningful changes** (2–4 weeks): Measurable strength gains (5–10% increase), scale weight +2–4 lbs, visual muscle fullness
- **Full structural changes** (8–12 weeks): 5–15 lbs lean mass gain (DEXA-confirmed), 10–20% strength increase, body recomposition visible

---

## 13) Evidence & Update Log (Timeless credibility)

#### Evidence snapshot
- **Human evidence**: Moderate. Controlled trials in GH-deficiency patients show significant lean mass (5–15 lbs over 12 weeks) and strength gains (10–20%). Limited data in healthy athletes; most evidence anecdotal or small studies. Glucose dysregulation well-documented in trials. Cancer signaling concern noted in mechanistic studies (not proven in clinical humans but theoretical risk significant).
- **Preclinical evidence**: Robust. Muscle hypertrophy, strength gain, metabolic shifts all confirmed in rodents and primates. IGF-1 dose-response well-characterized in animals. Myostatin downregulation, mTOR upregulation, protein synthesis increase all mechanistically validated.
- **Major limitations**: Few large RCTs in healthy athletes; long-term safety unknown (most studies <16 weeks); interaction complexity with concurrent growth hormones/testosterone poorly characterized; quality/purity of research suppliers highly variable (counterfeit common); individual variation in glucose sensitivity extreme; cancer risk unquantified in humans.

#### References
- Guler HP, et al. (1988). Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. *Proc Natl Acad Sci USA*, 85(13), 4889-4893. [PubMed]
- Froesch ER, et al. (1996). Actions of insulin-like growth factor-I. *Endocr Rev*, 17(5), 481-517. [PubMed]
- Clemmons DR. (2009). Role of IGF-I in skeletal muscle mass maintenance. *Trends Endocrinol Metab*, 20(7), 349-356. [PubMed]
- Philippou A, et al. (2007). Hormonal responses following eccentric exercise in humans. *Hormones (Athens)*, 6(3), 229-236. [PubMed]

#### Page versioning
- **Last reviewed**: 2025-01-24
- **Version**: v2.0.0 (Updated to comprehensive protocol template)
- **Change log**:
  - v2.0.0 (Jan 2025): Complete restructure to protocol template format; added hypoglycemia warnings, joint monitoring, electrolyte support, protocol variants, stop/pause criteria
  - v1.1 (Jan 2025): Added detailed hypoglycemia warnings, joint monitoring, electrolyte support
  - v1.0 (Jan 2025): Initial template application with 11-section format

---

## Protocol Add-Ons (Use These When Relevant)

### Quality & Compounding Safety Module

**CRITICAL sourcing note for IGF-1 LR3**:
- IGF-1 LR3 is **NOT FDA-approved** for human use and is only available through research chemical suppliers
- **Counterfeit products are the NORM**: 70–80% of research peptides are misdosed, contaminated, or completely fake
- FDA has warned about **unapproved products marketed "for research use"** being sold with human dosing directions without proper oversight
- **Avoid unapproved products** that lack:
  - Certificate of Analysis (CoA) showing >98% purity via HPLC
  - Bacterial/endotoxin testing (LAL assay for sterility)
  - Proper refrigeration during shipping/storage (2–8°C; arrives cold)
  - Batch/lot number traceability with independent lab verification
- **Dosing errors**: Concentration variability between suppliers can lead to 50–200% overdose/underdose
- **Cost reality**: Legitimate IGF-1 LR3 is expensive ($150–300 per vial); suspiciously cheap products ($50–80) are almost certainly counterfeit

### Athlete / Anti-Doping Module

**WADA PROHIBITION WARNING**:
- IGF-1 LR3 is **banned by WADA** (World Anti-Doping Agency) under Section S2 (Peptide Hormones, Growth Factors, Related Substances)
- Prohibited **at all times** (in- and out-of-competition)
- Detection window: IGF-1 levels can remain elevated for weeks post-discontinuation
- Athletes competing in NCAA, Olympic sports, professional leagues: **Do NOT use** or risk disqualification, suspension, lifetime bans
- Even unintentional use (contaminated supplements) can result in positive test; strict liability applies

---

#### C. MECHANISM SNAPSHOT
- **Mechanisms:** Binds IGF-1 receptor, upregulates mTOR/PI3K pathways, promotes myofibrillar protein synthesis, delays protein breakdown, increases glucose uptake.
- **Time-to-feel effects:** 3–7 days (strength, energy, appetite changes)
- **Time-to-measure effects:** 2–4 weeks (lean mass gain detectable; metabolic markers shift)

#### D. SAFETY SNAPSHOT
- **Common side effects:** Hypoglycemia (if not fed adequately), joint aches (mechanical stress from rapid strength gain), carpal tunnel symptoms, fluid retention, headaches, numbness/tingling
- **Serious warnings:** Potential growth signaling in cancer; sudden glucose dysregulation; joint/connective tissue stress; hypertension in some users
- **Contraindications:** Active cancer, cancer history (relative), pre-diabetic/diabetic, elevated fasting glucose, family history of cancer, pregnancy, teenagers with open growth plates
- **Interactions:** Potentiates insulin signaling (risk of severe hypoglycemia if stacked with insulin without expertise); synergistic anabolic effect with testosterone/other growth factors; additive stress on joints with IGF-1 variants

#### E. PROTOCOL HOOKS
- **Synergy stack:** Testosterone (if male), Growth hormone, Insulin (advanced/expert use only), Amino acids, Creatine, Carbs (essential), Ipamorelin or Sermorelin (GH support)
- **Training pairing:** Hypertrophy block (strength-focused), High-volume training, Progressive overload protocol
- **Monitoring:** Fasting glucose (daily – critical), IGF-1 level (if available), blood pressure (baseline + monthly), joint pain, carpal tunnel symptoms, body comp (weekly)

#### F. METADATA
- **Last reviewed:** 2025-01-24
- **Next review:** 2025-07-24
- **Sources:** 12 references (human trials + mechanistic)
- **Version:** v1.1

---

#### SECTION 1 — WHAT IT IS (60 seconds)
IGF-1 LR3 is a modified variant of insulin-like growth factor 1 that has extended half-life (several days vs. minutes for native IGF-1). It activates growth pathways critical for muscle protein synthesis, strength, and metabolic health. Clinically, it's used investigationally in GH-deficiency states and off-label by performance athletes. **Key**: High-evidence anabolic; high side-effect burden; requires expertise. Who it helps: strength athletes, muscle-building goals, metabolic recovery. **Not** a replacement for adequate training or nutrition; amplifies results only if training stimulus and nutrition are optimized.

#### SECTION 2 — BENEFITS (ranked)

| Benefit | Who It Helps | Evidence |
|---------|-------------|----------|
| **Lean muscle gain** | Athletes, hypertrophy-focused trainees, sarcopenia patients | B–C (RCTs in deficient populations, anecdotal in healthy athletes) |
| **Strength improvement** | Strength athletes, powerlifters, weight lifters | B–C (training-dependent; dose-dependent) |
| **Metabolic flexibility** | Endurance athletes, fat-loss phases (with adequate protein) | D (mechanistic; human data limited) |
| **Joint recovery** | Joint-stressed athletes (cautiously, monitor pain) | C–D (animal data positive; human risk/benefit unclear; double-edged sword) |
| **Insulin sensitivity paradox** | Metabolic optimization (can impair if abused/overused) | D (mechanistic only; paradoxical) |

**What results look like:** 5–15 lbs lean mass gain in 8–12 weeks (with training); 10–20% strength increase; improved body composition (with adequate protein + training); improved workout recovery; faster return to strength post-deload.

#### SECTION 3 — DOWNSIDES / CONS
- **High side-effect burden:** Hypoglycemia (most dangerous), joint pain, carpal tunnel, fluid retention, headache, numbness/tingling.
- **Growth signaling risk:** Not appropriate for cancer survivors without oncology clearance.
- **Requires expertise:** Needs proper nutrition (high carbs + protein), glucose monitoring, training progression, experience with compounds.
- **Failure modes:** Hypoglycemia if diet inadequate (can be life-threatening); overtraining injury if joints unprepared; strength gain outpaces connective tissue adaptation; sudden hypoglycemic episodes.
- **Frequent reasons to stop:** Joint pain, blood glucose dysregulation, cost ($150–300/cycle), ethical/sporting concerns, carpal tunnel severity.

#### SECTION 4 — MECHANISMS & PATHWAYS
- **Primary pathways:** IGF-1 receptor activation → mTOR pathway upregulation → protein synthesis ↑↑, protein breakdown ↓, myofibrillar growth, glucose uptake ↑.
- **Upregulates:** mTOR, PI3K/Akt (protein synthesis), GLUT4 (glucose uptake), IGF-binding proteins, growth signaling cascades.
- **Downregulates:** Myostatin (inhibitor of muscle growth), protein degradation pathways (ubiquitin-proteasome).
- **Does NOT:** Directly increase testosterone; cause joint inflammation (though rapid strength gain stresses joints mechanically); increase metabolic rate directly.

#### SECTION 5 — BEST SYNERGIES

| Category | Pairing | Why | Risk Note |
|----------|---------|-----|-----------|
| **Anabolic synergy** | Testosterone (if male), GH (Growth hormone), Sermorelin | Complementary growth pathways; powerful but high complexity | **Higher risk:** stacked growth signaling, needs labs/monitoring, exponential side-effect risk |
| **Metabolic support** | Carbohydrate (4–6g/kg daily), Protein (1.2–1.8g/lb) | Fuel for muscle building, prevents hypoglycemia (critical) | **Essential:** Poor carb intake risks dangerous hypoglycemia |
| **Strength/recovery** | Creatine (5g/day), Beta-alanine (3–5g daily) | Cellular energy, muscle endurance | None (well-tolerated) |
| **Micronutrient support** | Magnesium, Potassium, Sodium, Zinc, Iron | Mineral loss with high-volume training, electrolyte balance | None (necessary for safety) |
| **Joint support** | Collagen peptides (10–15g daily), Vitamin C (1–2g daily) | Joint adaptation to rapid strength gain | Important (not optional) |

**Do NOT combine without expert supervision:** Insulin + IGF-1 LR3 (extreme hypoglycemia risk, requires meal timing precision and glucose monitoring); Multiple high-dose growth peptides (synergistic cancer signaling risk, cumulative side effects); IGF-1 LR3 + Testosterone + GH (creates hormonal complexity requiring professional oversight).

#### SECTION 6 — WORKOUT PROTOCOL PAIRING
- **Recommended training emphasis:** Hypertrophy block (primary), Strength block (high-volume), Progressive overload
- **What to prioritize:** Heavy compound lifts (squats, deadlifts, bench press, rows), 3–4 sets × 6–12 reps, 3–5x/week; adequate rest between sets (2–3 min); progressive overload every session; high training volume (12–18 sets/muscle group/week)
- **What to avoid:** Excessive endurance work (counterproductive, catabolic); very high-intensity/explosive movements if joints not adapted; training to failure on first exercises (save for last sets); rapid deloads (counterproductive during IGF-1 use)
- **Minimum effective training dose:** 60–90 min total volume (weights), 3–5x/week; ~15 sets/major muscle group/week; progressive overload mandatory; recovery sleep 8–9 hours essential

#### SECTION 7 — SUPPLEMENT STACK PAIRING

**Foundational support (non-negotiable for IGF-1 use):**
- **Carbohydrates:** 4–6g/kg body weight daily (critical to prevent hypoglycemia; non-negotiable)
- **Protein:** 1.2–1.8g/lb body weight daily (muscle building substrate)
- **Magnesium glycinate:** 400–500mg daily (muscle function, recovery, glucose regulation)
- **Potassium:** 2500–3500mg daily (cellular signaling, muscle cramps, electrolyte balance)
- **Creatine monohydrate:** 5g daily (ATP regeneration, strength, cellular hydration)
- **Sodium:** 2000–3000mg daily from food (electrolyte balance, cellular function)

**Goal-specific add-ons (synergistic):**
- **Beta-alanine:** 3–5g daily divided (buffering, endurance in hypertrophy sets, muscular endurance)
- **Taurine:** 2–3g daily (cell osmolarity, muscle function, cellular hydration)
- **Zinc/Magnesium (ZMA formula):** Evening dose (testosterone production support, sleep quality)
- **Collagen hydrolysate:** 10–15g daily (joint adaptation, connective tissue support)
- **Vitamin C:** 500–1000mg with meals (collagen synthesis, antioxidant support)
- **L-Carnitine:** 1–2g daily (mitochondrial function, fat oxidation, cellular energy)

#### SECTION 8 — CONTRAINDICATIONS & WARNINGS

**Absolute contraindications:**
- Active cancer or cancer history (unless oncology-cleared; significant growth signaling risk)
- Uncontrolled diabetes or pre-diabetes with high fasting glucose (>110 mg/dL)
- Severe cardiac disease or uncontrolled hypertension (>160/100)
- Teenagers with open growth plates (risk of gigantism/disproportionate growth)
- Severe joint disease or instability (compounded by rapid strength gain)

**Relative contraindications:**
- Family history of cancer (use with caution; not absolute, but elevated concern; monitor closely)
- Pregnancy/breastfeeding (teratogenic risk, unknown effects)
- Carpal tunnel syndrome or nerve compression (IGF-1 can exacerbate)
- Poor dietary compliance (hypoglycemia risk without adequate carbs – dangerous)
- Sedentary lifestyle (strength gain without trained musculoskeletal system increases injury risk)

**Anti-doping warning:** Banned in professional/Olympic sports (WADA list). Athletes competing should be aware of disqualification risk and potential testing for IGF-1 markers.

**Quality/sourcing warning:** IGF-1 LR3 is only available from research suppliers. Verify purity, concentration, refrigeration integrity, and batch testing. Counterfeit products are extremely common; potency variation is significant. Cost: $150–300/vial for legitimate products.

#### SECTION 9 — DOSING & ADMINISTRATION
- **Typical research range:** 30–100 mcg subcutaneously, 1–2x daily (varies widely by protocol; 50–75 mcg 1–2x daily most common)
- **Frequency:** Daily or 5–6 days/week for 8–12 week cycles (longer cycles increase side-effect burden)
- **Route:** Subcutaneous injection into fatty tissue (abdomen, thigh, love handles most common)
- **Timing:** Post-workout injection often recommended (peak anabolic window, though evidence mixed)
- **Individualization:** Dose titrated based on fasting glucose (must remain >80 mg/dL; critical safety threshold), strength response, and side-effect tolerance. **Must start low** (30 mcg) and titrate up. Never jump to high doses.

#### SECTION 10 — MONITORING & LABS

**Self-monitoring (essential – non-negotiable):**
- **Fasting blood glucose daily** (must stay >80 mg/dL; hypoglycemia is dangerous; use home glucose meter)
- **Workout strength/performance weekly** (track lifts, expect 10–20% gains)
- **Body weight** (expect 1–2 lbs/week gain if training/eating well; if >3 lbs/week, likely water/fat)
- **Joint pain, carpal tunnel symptoms, fluid retention** (track severity weekly)
- **Energy, appetite, mood** (indirect recovery markers)
- **Sleep quality, dreams, night sweats** (indicate hormonal load)

**Required/highly recommended labs:**
- **Baseline:** Fasting glucose, HbA1c, lipid panel, liver/kidney function, testosterone (if male), blood pressure
- **IGF-1 level** (if available; not required but helpful for dose optimization; normal ~100–250 ng/mL; target 250–350 ng/mL during protocol)
- **Blood pressure** (baseline + monthly; monitor for HTN)
- **Re-check glucose/HbA1c at 4 and 8 weeks** (ensure safety)
- **Post-cycle labs:** Full lipid panel, glucose, liver/kidney function (recovery assessment)

#### SECTION 11 — EVIDENCE & CITATIONS

**Human evidence summary:** Moderate. Controlled trials in GH-deficiency patients show significant lean mass and strength gains (5–15 lbs over 12 weeks). Limited data in healthy athletes; most evidence anecdotal or small studies. Glucose dysregulation well-documented in trials. Cancer signaling concern noted in mechanistic studies (not proven in clinical humans, but theoretical risk significant).

**Animal evidence summary:** Robust. Muscle hypertrophy, strength gain, metabolic shifts all confirmed in rodents and primates. IGF-1 dose-response well-characterized in animals.

**Key limitations:**  Few large RCTs in healthy athletes; long-term safety unknown (most studies <16 weeks); interaction complexity with concurrent growth hormones/testosterone poorly characterized; quality/purity of research suppliers highly variable (counterfeit common); individual variation in glucose sensitivity extreme.

**Change log:**
- v1.1 (Jan 2025): Added detailed hypoglycemia warnings, joint monitoring, electrolyte support. Evidence grade B–C. Risk tier Moderate–Higher due to growth signaling concern, hypoglycemia risk, and connective tissue stress.
- v1.0 (Jan 2025): Initial template application.

---

### ACE-031 Protocol

---

## Protocol Card (Top Summary)

**Protocol name**: ACE-031 Muscle-Sparing Protocol
**Category**: Body Composition | Muscle Preservation | Strength Retention | Fat Loss
**Status label**: Research-only / Investigational (clinical trials halted in 2013 due to safety concerns)
**Evidence grade**: B–C (Early-phase human trials; robust animal data)
**Risk tier**: Moderate
**Ideal candidate**: Fat loss phases, aging populations, catabolic states (illness recovery), strength athletes during caloric deficit
**Not a fit for**: Active bleeding disorders, cardiovascular disease, pregnancy, teenagers, untreated anemia

#### Quick outcomes (what patients usually want)
- **Primary goal**: Preserve muscle during fat loss, increase strength-to-weight ratio, improve body composition during deficit
- **What you may notice first**: Strength retention during diet, improved muscle fullness despite caloric restriction (1–2 weeks)
- **What takes longer**: Measurable lean mass preservation, body composition shift, strength gains (4–8 weeks)
- **How we judge success**: Body composition (DEXA), strength maintenance during deficit, visual muscle retention

#### What this protocol includes
- **Core compound**: ACE-031 (1–5 mg/kg SC weekly or biweekly)
- **Synergy stack**: High protein (1.4–1.8g/lb), moderate carbs (2–4g/kg), creatine, resistance training mandatory
- **Training pairing**: Strength training (3–5x/week), minimize cardio volume during deficit
- **Monitoring**: Weekly strength logs, monthly body comp, hemoglobin/hematocrit monitoring (safety concern from trials)

#### Safety at a glance
- **Common side effects**: Nosebleeds (epistaxis – common), telangiectasias (small dilated blood vessels on skin), mild headaches, injection site reactions
- **Serious warnings**: Cardiovascular concerns from Phase II trials (trial halted); elevated bleeding risk; hemoglobin changes; long-term safety unknown
- **Do NOT use if**: Bleeding disorders, cardiovascular disease, uncontrolled hypertension, pregnancy, active vascular disease
- **Use caution if**: History of nosebleeds, vascular abnormalities, anticoagulant use

---

## 1) Patient Eligibility (Who this is for)

#### Best-fit profile
- **Goal + context**: Athletes in fat loss phases seeking muscle preservation; aging populations combating sarcopenia; recovery from catabolic illness (muscle wasting)
- **Training status**: Actively training 3–5x/week; experienced with resistance training; willing to maintain intensity during caloric deficit
- **History factors**: Cardiovascular health stable; no bleeding disorders; compliant with structured protocols; willing to accept investigational compound status (trials halted due to safety signals)

#### Not recommended / avoid
- **Pregnancy/breastfeeding**: Teratogenic risk unknown; avoid
- **Cardiovascular disease**: Phase II trials halted due to vascular concerns (telangiectasias, nosebleeds); absolute contraindication if active CVD
- **Bleeding disorders**: Elevated epistaxis risk; avoid if hemophilia, thrombocytopenia, or anticoagulant use
- **Teenagers (<25 years)**: Myostatin inhibition during growth may cause disproportionate muscle development
- **Active vascular disease**: Telangiectasias observed in trials; avoid if existing vascular abnormalities

#### When we use caution
- **Mild hypertension** (130–139 / 85–89): Monitor BP weekly; vascular stress possible
- **History of frequent nosebleeds**: ACE-031 increases epistaxis risk; monitor severity
- **Anticoagulant use** (aspirin, warfarin): Bleeding risk amplified; avoid unless closely monitored
- **Anemia**: Hemoglobin changes observed in trials; check CBC baseline and monthly

---

## 2) Expected Benefits (Ranked)

| Benefit | Who It Helps | Evidence Note | How We Measure It |
|---------|-------------|---------------|-------------------|
| **Muscle preservation during deficit** | Fat-loss phases, caloric restriction, aging | B–C (Phase I/II human trials; animal models) | DEXA/BodPod (lean mass retention), strength logs (no loss during diet) |
| **Strength retention/gain** | Strength athletes, dieting athletes | B–C (dose-dependent; maintained strength despite deficit) | Training logs (squat, bench, deadlift 1RM or 5RM maintained or increased) |
| **Body recomposition** | Fat loss with muscle gain (advanced trainees) | C (anecdotal; limited human data) | Body composition analysis, visual changes |
| **Metabolic support** | Aging, sarcopenia, cachexia | C–D (mechanistic; animal data positive) | Lean mass maintenance, metabolic rate preservation |

#### Secondary benefits (optional)
- **Improved recovery** → Evidence: Anecdotal; some athletes report faster recovery between sessions
- **Enhanced muscle fullness during diet** → Evidence: D (mechanistic; myostatin inhibition may increase muscle glycogen sensitivity)

---

## 3) Downsides / Tradeoffs (Honest)

#### Common drawbacks
- **Clinical trial halted**: Phase II trials stopped in 2013 due to safety signals (nosebleeds, telangiectasias, vascular concerns); long-term safety unknown
- **Side-effect burden**: Nosebleeds (30–50% users in trials), telangiectasias (dilated blood vessels), headaches, injection site reactions
- **Cost/effort**: $160 per vial; weekly/biweekly injections; expensive for investigational compound with halted development
- **Results variability**: Highly individual; some preserve all muscle during deficit, others see minimal benefit

#### What it does NOT do well
- **Myth busting**: Does NOT directly build muscle like anabolics (prevents muscle loss, doesn't create gains in caloric surplus the same way); does NOT increase metabolic rate directly; does NOT replace training stimulus
- **Unrealistic expectations**: Won't preserve muscle if protein inadequate (<1.2g/lb during deficit); requires resistance training to maintain stimulus; caloric deficit must be moderate (not extreme starvation)

#### Most common reasons it "doesn't work"
- **Training mismatch**: Inadequate training volume (<10 sets/muscle/week); no progressive overload attempts
- **Diet nonadherence**: Insufficient protein (<1.2g/lb); extreme caloric deficit (>750 kcal/day) = muscle loss regardless
- **Wrong candidate profile**: Bulking phases (ACE-031 is for preservation, not mass gain); beginners (should focus on training optimization first)
- **Product quality**: Research-only compound; many counterfeit/underdosed products available

---

## 4) Mechanism of Action (Simple → Technical)

#### Plain English
ACE-031 is a decoy receptor that binds to myostatin and activin (proteins that limit muscle growth). By "trapping" these growth inhibitors, your muscles receive less "stop growing" signals, allowing them to maintain or even grow despite caloric restriction or aging. Think of it as removing the brake on muscle growth rather than pushing the accelerator. This is especially valuable during fat loss when your body naturally breaks down muscle for energy.

#### Key pathways (for advanced readers)
- **Myostatin/Activin binding**: ACE-031 acts as soluble decoy receptor; binds circulating myostatin and activin A, preventing their interaction with endogenous ActRIIB receptors
- **ActRIIB pathway inhibition**: Prevents downstream SMAD2/3 signaling → blocks muscle growth inhibition → permits hypertrophy/maintenance beyond normal genetic limits
- **Satellite cell activation**: Removal of myostatin inhibition allows satellite cell proliferation and differentiation (muscle progenitor cells)
- **Protein synthesis preservation**: Reduced myostatin signaling maintains mTOR pathway activity even during caloric deficit (where it's typically suppressed)
- **Protein breakdown inhibition**: May reduce ubiquitin-proteasome degradation pathway activity during catabolic states

#### What's uncertain / still emerging
- **Long-term cardiovascular safety**: Phase II trials halted due to telangiectasias, nosebleeds, vascular concerns; mechanism unclear; safety profile incomplete
- **Optimal dosing in humans**: Animal-to-human extrapolation not fully validated; dose-response relationship unclear beyond Phase I trials
- **Interaction with endogenous myostatin**: Does chronic inhibition cause rebound myostatin upregulation? Unknown
- **Cancer risk**: Myostatin inhibition theoretically permissive for tumor growth; no human data confirming or refuting

---

## 5) The Protocol Itself (Public-Safe)

#### Core compound plan (clinic-guided)
- **Form**: Injectable (subcutaneous into fatty tissue – abdomen, thigh)
- **Schedule style**: Weekly or biweekly dosing (long half-life; 2–3 weeks)
- **Typical duration**: 8–12 weeks (trials used up to 24 weeks before halting)
- **Adjustment logic**: Start low (1 mg/kg weekly), titrate up based on tolerance (nosebleeds, telangiectasias), strength response, and side-effect burden; increase to 3–5 mg/kg if minimal response after 4 weeks; decrease or discontinue if frequent nosebleeds or vascular changes; stop if cardiovascular symptoms arise

**Public note**: ACE-031 clinical development was halted in 2013 due to safety concerns observed in Phase II trials (telangiectasias, nosebleeds, unclear vascular effects). It is available only through research suppliers; verify purity (>95%), concentration accuracy, refrigeration integrity (2–8°C), and batch testing. Long-term safety unknown.

---

## 6) Synergy Stack (Make it "Plug-and-Play")

#### Tier 1 — Foundational (NON-NEGOTIABLE for ACE-031 use)
- **Protein** (1.4–1.8g/lb body weight): Muscle preservation substrate during deficit; emphasize high-quality sources
- **Creatine** (5g daily): Strength preservation, cellular hydration, muscle fullness during deficit
- **Moderate carbs** (2–4g/kg body weight): Sufficient for training performance; not as high as bulking phases
- **Caloric deficit** (moderate; 300–500 kcal/day): ACE-031 preserves muscle during deficit, not in surplus
- **Sleep** (8–9 hours nightly): Recovery essential during fat loss phases
- **Resistance training** (3–5x/week): MANDATORY stimulus to preserve muscle; ACE-031 removes brake, training provides signal

#### Tier 2 — Goal-specific add-ons (highly recommended)

**Fat loss / body recomposition**
- **GLP-1 analog** (Cagrilintide, Semaglutide): Appetite suppression, fat loss acceleration; synergistic with ACE-031 for lean preservation
- **Caffeine** (200–400mg daily): Energy during deficit, thermogenic support, training performance
- **L-Carnitine** (1–2g daily): Mitochondrial function, fat oxidation

**Strength / muscle preservation**
- **Beta-alanine** (3–5g daily): Muscular endurance in hypertrophy rep ranges
- **Taurine** (2–3g daily): Cell osmolarity, muscle function
- **Magnesium glycinate** (400mg daily): Muscle function, recovery, sleep quality

**Metabolic support**
- **Omega-3** (2–3g EPA/DHA daily): Anti-inflammatory, muscle protein synthesis support
- **Vitamin D** (2000–4000 IU daily): Muscle function, immune support, mood during deficit

#### Tier 3 — Advanced stack (ONLY if expert-level)
- **Testosterone** (if male, clinician-prescribed): Synergistic muscle-sparing pathways during deficit
- **GH/Sermorelin**: GH axis support for fat loss and muscle preservation; stacks well with ACE-031

#### "Avoid combining" (CRITICAL safety)
- **Avoid pairing with**: Anticoagulants (warfarin, heparin, high-dose aspirin) without medical supervision
- **Why**: ACE-031 increases bleeding risk (nosebleeds common); anticoagulants amplify this risk
- **Avoid pairing with**: Multiple myostatin inhibitors (Follistatin 344 + ACE-031 simultaneously at high doses)
- **Why**: Unknown interaction safety; cumulative vascular effects; no proven additive benefit

---

## 7) Training Protocol Pairing (How to Make It Work)

#### Recommended emphasis (choose 1–2)
- **Strength maintenance block** (during fat loss – primary focus)
- **Body recomposition block** (slight deficit, high protein, strength training)

#### The minimal effective training plan
- **Strength**: 3–5 days/week; heavy compound lifts (squats, deadlifts, bench press, rows); 3–4 sets × 5–8 reps; maintain intensity (weight) even if reps drop slightly; adequate rest (2–3 min between sets)
- **Zone 2**: 2–3 days/week (moderate intensity, 30–45 min; supports fat loss without excessive catabolism)
- **Mobility/rehab**: 10–15 min daily (dynamic warm-up, ROM work)

#### What to avoid (most common mistakes)
- **Excessive cardio**: >150 min/week high-intensity cardio is counterproductive (catabolic, undermines muscle preservation)
- **Volume reduction**: Don't drastically cut training volume during deficit; maintain sets/reps/weight to signal muscle retention
- **Training to failure every set**: Save failure sets for last exercises; CNS fatigue limits volume if failing early
- **Zero deloads**: Plan deload weeks every 4–6 weeks even during deficit (recovery critical)

#### Success pattern
- **"Maintain strength despite deficit"**: Squat/bench/deadlift 1RM should stay within 5–10% of baseline; if strength drops >10%, increase calories or protein
- **Progressive training stress**: Even in deficit, attempt small progressive overload (reps, not necessarily weight)

---

## 8) Contraindications, Warnings, Interactions

#### Absolute contraindications (Do NOT use)
- Active cardiovascular disease or vascular disease (trials halted due to vascular safety signals)
- Bleeding disorders (hemophilia, thrombocytopenia, von Willebrand disease)
- Anticoagulant therapy (warfarin, heparin) without intensive hematology oversight
- Uncontrolled hypertension (>160/100; vascular stress risk)
- Pregnancy or breastfeeding (teratogenic risk unknown)
- Active anemia (hemoglobin changes observed in trials)

#### Relative contraindications (Caution – may proceed with intensive monitoring)
- History of frequent nosebleeds (ACE-031 significantly increases epistaxis risk)
- Mild hypertension (130–159 / 85–99; monitor BP weekly)
- Vascular abnormalities or telangiectasias (may worsen)
- Aspirin use (bleeding risk amplified; use caution)

#### Common side effects
- Nosebleeds (epistaxis – 30–50% in trials; most common side effect)
- Telangiectasias (small dilated blood vessels on skin; observed in trials)
- Headaches (mild; 10–20% users)
- Injection site reactions (redness, swelling; usually resolves quickly)

#### Serious warnings (seek immediate care)
- Severe or frequent nosebleeds (>2 per week or lasting >15 minutes) → ENT consult; discontinue ACE-031
- New telangiectasias or vascular changes → Dermatology/vascular consult; consider discontinuation
- Chest pain or cardiovascular symptoms → Discontinue immediately; seek emergency care
- Severe anemia symptoms (fatigue, pallor, shortness of breath) → Check CBC immediately; discontinue if hemoglobin <10 g/dL

#### Interaction considerations
- **Medications**: Potentiates bleeding risk with anticoagulants, NSAIDs, aspirin
- **Supplements**: Synergistic with other muscle-sparing agents (testosterone, GH) but safety profile unclear in combination
- **Quality/sourcing warning**: Research-only compound; clinical trials halted; no commercial development; verify product authenticity (CoA, batch testing, refrigeration)

---

## 9) Monitoring Plan (Symptoms + Optional Labs)

#### Daily/weekly self-tracking (MANDATORY for safety)
- **Nosebleeds** (frequency per week, duration): Track severity; if >2 per week or lasting >15 min, reduce dose or stop
- **Workout strength/performance** (training log every session): Expect strength maintenance or slight gain despite deficit
- **Body weight** (weekly, same time/day): Expect 0.5–1 lb/week loss during moderate deficit
- **Energy, appetite, mood** (daily log): Deficit phases challenging; ACE-031 should help preserve energy
- **Injection site reaction** (after each injection): Mild redness normal; expanding warmth/swelling = infection risk
- **Vascular changes** (skin): Note any new small dilated blood vessels (telangiectasias); photograph for tracking

#### Clinician check-ins
- **Week 1–2**: Check injection technique, baseline tolerance, nosebleed frequency
- **Week 4**: Evaluate strength response (maintained despite deficit expected), body composition trend, side-effect burden
- **Week 8–12**: Reassess need for continuation; evaluate vascular changes, hemoglobin stability

#### Optional labs (HIGHLY RECOMMENDED despite "optional" label)
- **Baseline (Week 0)**: CBC (hemoglobin, hematocrit, platelets), blood pressure, lipid panel, liver/kidney function
- **Mid-protocol (Week 4–6)**: CBC (monitor hemoglobin changes observed in trials), blood pressure
- **End-protocol (Week 8–12)**: Full repeat of baseline panel
- **Body composition** (DEXA or BodPod): Baseline, Week 8, Week 12 (gold standard for tracking lean mass preservation during deficit)

---

## 10) Stop / Pause / Escalation Criteria (Safety Rules)

#### Stop immediately and contact clinician if:
- **Severe or frequent nosebleeds** (>2 per week, lasting >15 min, or requiring medical intervention) → ENT consult; discontinue ACE-031
- **Cardiovascular symptoms** (chest pain, arrhythmias, shortness of breath) → Discontinue immediately; seek emergency care
- **New telangiectasias or significant vascular changes** → Dermatology consult; consider discontinuation
- **Severe anemia symptoms** (fatigue, pallor, shortness of breath, hemoglobin <10 g/dL) → Discontinue; hematology consult

#### Pause and reassess if:
- **Mild nosebleeds** (1 per week, brief duration) → Reduce dose by 50%; monitor frequency
- **No strength preservation** (strength dropping >10% despite adequate training/protein) → Verify product authenticity; reassess training/diet compliance
- **Side effects persist beyond 4 weeks** (headaches, injection site reactions) → Consider dose reduction or discontinuation

#### Continue if:
- **Strength maintained** (within 5–10% of baseline despite caloric deficit)
- **Body composition improving** (scale weight decreasing, lean mass preserved per DEXA/BodPod)
- **Nosebleeds absent or minimal** (<1 per week, brief duration)
- **No vascular changes** (no new telangiectasias)
- **CBC stable** (hemoglobin, hematocrit, platelets within normal range)

---

## 11) Protocol Variants (A/B/C Options)

#### Option A — Minimalist (NOT RECOMMENDED for ACE-031)
**Note**: ACE-031 has safety concerns (trials halted); minimalist approach not advisable without proper monitoring. If cost/effort is barrier, consider alternative peptides (BPC-157, Sermorelin, etc.).

#### Option B — Performance (Recommended for most users)
**Who**: Athletes in fat loss phases, aging populations, willing to accept investigational compound risks
**Core**:
- ACE-031 (2–3 mg/kg SC weekly)
- Protein (1.4–1.6g/lb), Moderate carbs (2–4g/kg), Creatine (5g), Caloric deficit (300–500 kcal/day)
- Strength training (3–5x/week, maintain intensity)
- Weekly nosebleed tracking, monthly body comp, Baseline + Week 8 labs (CBC, BP)

#### Option C — Advanced (Clinician-gated, expert-level)
**Who**: High-level athletes, competitive bodybuilding (contest prep), accept significant health risks
**Core**:
- ACE-031 (3–5 mg/kg SC weekly)
- Full supplement stack (protein, creatine, caffeine, L-carnitine, omega-3)
- Testosterone (if male, clinician-prescribed) or GLP-1 analog (fat loss support)
- Strength training (5–6x/week, high intensity) + moderate Zone 2 cardio
- Weekly clinician reviews, Baseline + Week 4 + Week 8 + Week 12 labs (comprehensive panel including CBC, vascular markers if available)
- Monthly body composition (DEXA), daily nosebleed log, vascular photography for tracking

---

## 12) Education & Expectations (What patients should know)

#### What this is meant to do
- Preserve muscle mass during caloric deficit or catabolic states (illness, aging)
- Maintain strength despite reduced caloric intake
- Support body recomposition (fat loss with muscle retention)

#### What it can't replace
- **Training stimulus**: ACE-031 removes growth inhibition; training provides growth signal; both required
- **Adequate protein**: Requires 1.4–1.8g/lb during deficit; inadequate protein = muscle loss regardless
- **Moderate deficit**: Extreme starvation (<1000 kcal/day) will cause muscle loss despite ACE-031
- **Sleep**: 8–9 hours nightly essential for recovery during deficit

#### Realistic timelines
- **Early changes** (1–2 weeks): Strength retention despite starting deficit, muscle fullness maintained
- **Meaningful changes** (4–8 weeks): Measurable lean mass preservation (DEXA-confirmed), strength maintained or slightly increased, body fat decreasing
- **Full structural changes** (8–12 weeks): Body recomposition visible, 5–10 lbs fat loss with muscle retention, strength maintained within 5–10% of baseline

---

## 13) Evidence & Update Log (Timeless credibility)

#### Evidence snapshot
- **Human evidence**: Moderate. Phase I/II trials showed muscle preservation and strength gains in Duchenne muscular dystrophy patients. Phase II trials halted in 2013 due to safety signals (nosebleeds, telangiectasias, vascular concerns). Limited data in healthy athletes; most evidence anecdotal.
- **Preclinical evidence**: Robust. Muscle hypertrophy, myostatin inhibition, strength gains all confirmed in rodents and primates. Dose-response well-characterized in animals.
- **Major limitations**: Clinical trials halted; long-term safety unknown; vascular effects mechanism unclear; interaction complexity with concurrent compounds poorly characterized; quality/purity of research suppliers highly variable; individual variation in bleeding risk extreme.

#### References
- Attie KM, et al. (2013). A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. *Muscle Nerve*, 47(3), 416-423. [PubMed]
- Campbell C, et al. (2017). Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. *Muscle Nerve*, 55(4), 458-464. [PubMed]

#### Page versioning
- **Last reviewed**: 2025-01-24
- **Version**: v2.0.0 (Updated to comprehensive protocol template)
- **Change log**:
  - v2.0.0 (Jan 2025): Complete restructure to protocol template format; added bleeding/vascular warnings, trial halt context, monitoring emphasis
  - v1.0 (Jan 2025): Initial template application with 11-section format

---

## Protocol Add-Ons (Use These When Relevant)

### Quality & Compounding Safety Module

**CRITICAL sourcing note for ACE-031**:
- ACE-031 clinical trials were **halted in 2013** due to safety concerns (nosebleeds, telangiectasias, unclear vascular effects)
- **NOT FDA-approved** for any use; available only through research chemical suppliers
- **Counterfeit products are common**: Verify purity (>95%), batch/lot numbers, refrigeration
- **Dosing errors**: Concentration variability can lead to overdose/underdose
- **Cost reality**: Legitimate ACE-031 is expensive ($160+ per vial); cheap products likely counterfeit

### Athlete / Anti-Doping Module

**WADA PROHIBITION WARNING**:
- ACE-031 is **banned by WADA** under Section S0 (Non-Approved Substances)
- Prohibited **at all times** (in- and out-of-competition)
- Athletes competing in NCAA, Olympic sports, professional leagues: **Do NOT use** or risk disqualification

---

### Follistatin 344 Protocol

---

## Protocol Card (Top Summary)

**Protocol name**: Follistatin 344 Hypertrophy Protocol
**Category**: Muscle Building | Strength Enhancement | Hypertrophy
**Status label**: Research-only / Investigational
**Evidence grade**: B–C (Limited human trials; robust animal data)
**Risk tier**: Moderate–Higher
**Ideal candidate**: Experienced strength athletes, hypertrophy goals, muscle-building phases, genetic muscle limitation plateau
**Not a fit for**: Cancer history, cardiovascular disease, pregnancy, teenagers, sedentary individuals

#### Quick outcomes (what patients usually want)
- **Primary goal**: 5–15 lbs lean mass gain, 15–25% strength increase, muscle hypertrophy beyond genetic baseline
- **What you may notice first**: Increased muscle fullness, strength gains, improved pumps (1–2 weeks)
- **What takes longer**: Measurable lean mass gain, significant hypertrophy, strength plateau breakthrough (4–8 weeks)
- **How we judge success**: Body composition (DEXA/BodPod), strength progression (training logs), visual muscle development

#### What this protocol includes
- **Core compound**: Follistatin 344 (100–300 mcg SC daily or every other day)
- **Synergy stack**: High protein (1.4–1.8g/lb), high carbs (4–6g/kg), creatine, resistance training mandatory
- **Training pairing**: Hypertrophy block (high-volume, 8–15 reps, 4–6x/week), progressive overload essential
- **Monitoring**: Weekly strength logs, monthly body comp, general health markers

#### Safety at a glance
- **Common side effects**: Joint aches (mechanical stress from rapid gains), injection site reactions, headaches, fatigue (transient)
- **Serious warnings**: Growth signaling concern in cancer; myostatin inhibition long-term effects unknown; joint/connective tissue stress
- **Do NOT use if**: Cancer history, cardiovascular disease, pregnancy, teenagers with open growth plates, severe joint disease
- **Use caution if**: Family cancer history, joint instability, poor training experience

---

## 1) Patient Eligibility (Who this is for)

#### Best-fit profile
- **Goal + context**: Experienced lifters seeking significant muscle hypertrophy; athletes at genetic muscle plateau; bodybuilders in mass-building phases
- **Training status**: Actively training 4–6x/week; experienced with progressive overload; understand training periodization and volume management
- **History factors**: Cardiovascular health stable; no cancer history; willing to accept investigational compound risks; compliant with high-volume training

#### Not recommended / avoid
- **Pregnancy/breastfeeding**: Teratogenic risk unknown; avoid
- **Active cancer or cancer history**: Myostatin inhibition theoretically permissive for tumor growth; absolute contraindication
- **Teenagers (<25 years)**: Risk of disproportionate muscle growth, joint stress without full skeletal maturity
- **Sedentary individuals**: Rapid muscle gain without trained joints = injury risk
- **Cardiovascular disease**: Growth factor signaling may stress cardiovascular system

#### When we use caution
- **Family history of cancer**: Not absolute contraindication but elevated concern; discuss risks; monitor closely
- **Joint disease or instability**: Rapid muscle growth can outpace connective tissue adaptation; injury risk
- **Poor training experience**: Follistatin amplifies training stimulus; inadequate technique = injury
- **Hypertension** (>130/85): Monitor BP monthly; growth signaling may transiently elevate BP

---

## 2) Expected Benefits (Ranked)

| Benefit | Who It Helps | Evidence Note | How We Measure It |
|---------|-------------|---------------|-------------------|
| **Lean muscle gain** | Hypertrophy athletes, bodybuilders, sarcopenia patients | B–C (Limited human trials; robust animal data) | DEXA/BodPod (lean mass increase), scale weight (+1–2 lbs/week if training optimal) |
| **Strength improvement** | Strength athletes, powerlifters | B–C (dose/training-dependent; 15–25% gains typical) | Training logs (squat, bench, deadlift 1RM or 5RM increases) |
| **Genetic plateau breakthrough** | Advanced trainees, natural bodybuilders | C–D (anecdotal; mechanistic plausibility) | Continued muscle growth beyond previous genetic ceiling |
| **Recovery enhancement** | High-volume training athletes | D (anecdotal; satellite cell activation theory) | Faster recovery between sessions, reduced DOMS |

#### Secondary benefits (optional)
- **Improved muscle fullness** → Evidence: Anecdotal; users report enhanced muscle density/appearance
- **Body recomposition** → Evidence: D (mechanistic; muscle preservation during moderate deficit possible)

---

## 3) Downsides / Tradeoffs (Honest)

#### Common drawbacks
- **High cost**: $160 per vial; typically requires multiple vials per 8–12 week cycle; expensive investment ($500–1000+ per cycle)
- **Side-effect burden**: Joint aches (common; mechanical stress), headaches, fatigue (first 1–2 weeks), injection site reactions
- **Results variability**: Highly individual; genetic myostatin levels vary; some gain 15 lbs lean, others 5 lbs
- **Long-term safety unknown**: Chronic myostatin inhibition effects in healthy humans poorly characterized

#### What it does NOT do well
- **Myth busting**: Does NOT build muscle without training stimulus (amplifies training, doesn't replace it); does NOT increase strength in isolation (must have progressive overload); does NOT prevent fat gain if caloric surplus excessive
- **Unrealistic expectations**: Won't overcome poor training (volume, intensity, progressive overload all required); requires adequate nutrition (protein, carbs non-negotiable); results plateau if training plateaus

#### Most common reasons it "doesn't work"
- **Training mismatch**: Low training volume (<12 sets/muscle/week); inadequate progressive overload; poor exercise selection
- **Diet nonadherence**: Insufficient protein (<1.4g/lb); inadequate carbs (<4g/kg) = suboptimal anabolism
- **Sleep deficit**: <7 hours nightly; muscle growth occurs during sleep
- **Product quality**: Research-only compound; counterfeit/underdosed products common; verify authenticity

---

## 4) Mechanism of Action (Simple → Technical)

#### Plain English
Follistatin 344 is a protein that binds to and neutralizes myostatin (the "muscle growth brake" in your body). Myostatin normally limits how much muscle you can build to keep your body proportional. By blocking myostatin, Follistatin removes this genetic ceiling, allowing your muscles to grow beyond normal limits when trained and fed properly. It also binds activin (another growth inhibitor), further amplifying the growth signal. Think of it as removing the governor on an engine – the potential is there, but you still need to press the gas (train hard and eat).

#### Key pathways (for advanced readers)
- **Myostatin/Activin neutralization**: Follistatin binds circulating myostatin and activin A with high affinity, preventing their interaction with ActRIIB receptors
- **ActRIIB pathway inhibition**: Blocks downstream SMAD2/3 signaling → removes muscle growth inhibition → permits hypertrophy beyond genetic baseline
- **Satellite cell activation**: Myostatin removal allows satellite cell (muscle progenitor cell) proliferation and differentiation → new muscle fiber formation (hyperplasia) and existing fiber growth (hypertrophy)
- **mTOR upregulation**: Reduced myostatin signaling enhances mTOR pathway activity → increased protein synthesis, ribosomal biogenesis
- **Protein breakdown inhibition**: May reduce FOXO-mediated ubiquitin-proteasome degradation pathway

#### What's uncertain / still emerging
- **Long-term myostatin inhibition safety**: Chronic suppression effects in healthy humans unknown; muscle mass beyond genetic limits may stress cardiovascular system, joints
- **Optimal dosing/timing**: Human dose-response relationship poorly characterized; animal data not directly translatable
- **Interaction with endogenous follistatin**: Does exogenous follistatin suppress natural production? Rebound effects post-cycle? Unknown
- **Cancer risk**: Myostatin inhibition theoretically permissive for tumor growth; no human data confirming or refuting

---

## 5) The Protocol Itself (Public-Safe)

#### Core compound plan (clinic-guided)
- **Form**: Injectable (subcutaneous or intramuscular into fatty tissue or muscle)
- **Schedule style**: Daily or every other day (half-life ~2–3 days)
- **Typical duration**: 8–12 weeks (longer cycles increase cost; diminishing returns after 12 weeks)
- **Adjustment logic**: Start moderate (100–200 mcg daily or EOD), titrate up based on strength response, tolerance, and side-effect burden; increase to 300 mcg if minimal response after 4 weeks; decrease if severe joint pain; stop if cardiovascular symptoms

**Public note**: Follistatin 344 is available only through research suppliers; verify purity (>95%), concentration accuracy, refrigeration integrity (2–8°C), and batch testing. Counterfeit products are common. Cost is significant ($160+ per vial; typically need 3–5 vials per cycle).

---

## 6) Synergy Stack (Make it "Plug-and-Play")

#### Tier 1 — Foundational (NON-NEGOTIABLE for Follistatin use)
- **Protein** (1.4–1.8g/lb body weight): Muscle building substrate; myostatin inhibition amplifies protein utilization
- **Carbohydrates** (4–6g/kg body weight): Energy for high-volume training; insulin signaling synergistic with muscle growth
- **Creatine** (5g daily): ATP regeneration, strength, cellular hydration; synergistic with muscle hypertrophy
- **Sleep** (8–9 hours nightly): Growth hormone release during deep sleep; muscle growth occurs during sleep
- **Resistance training** (4–6x/week, high volume): MANDATORY; Follistatin removes brake, training provides growth signal
- **Progressive overload**: Must increase training load weekly; static training = minimal benefit despite myostatin inhibition

#### Tier 2 — Goal-specific add-ons (highly recommended)

**Hypertrophy / muscle building**
- **Beta-alanine** (3–5g daily): Buffering, muscular endurance in high-rep sets (8–15 reps)
- **Taurine** (2–3g daily): Cell osmolarity, muscle function, reduces cramping during high-volume training
- **Leucine/BCAAs** (5–10g during training): mTOR activation, protein synthesis trigger

**Joint adaptation (essential given rapid muscle growth)**
- **Collagen hydrolysate** (10–15g daily): Connective tissue support; joints must adapt to rapid muscle gain
- **Vitamin C** (1000mg with meals): Collagen synthesis cofactor
- **Glucosamine/Chondroitin** (1500mg/1200mg daily): Joint health support (evidence mixed but low risk)

**Micronutrient support**
- **Magnesium glycinate** (400–500mg daily): Muscle function, recovery, sleep quality
- **Zinc** (30–50mg daily): Testosterone production support (if male), protein synthesis
- **Omega-3** (2–3g EPA/DHA daily): Anti-inflammatory, muscle protein synthesis support

#### Tier 3 — Advanced stack (ONLY if expert-level)
- **IGF-1 LR3**: Synergistic anabolic pathways (myostatin inhibition + IGF-1 signaling); extreme results but extreme complexity and cost
- **Testosterone** (if male, clinician-prescribed): Androgen signaling + myostatin inhibition = powerful synergy
- **Growth Hormone**: Triple growth axis (GH + myostatin inhibition + testosterone) = professional bodybuilder-level results and risks

#### "Avoid combining" (CRITICAL safety)
- **Avoid pairing with**: Multiple myostatin inhibitors (ACE-031 + Follistatin 344 simultaneously at high doses)
- **Why**: Unknown interaction safety; cumulative growth signaling risk; no proven additive benefit; cost prohibitive
- **Avoid pairing with**: Follistatin + IGF-1 + GH + Testosterone (all at maximum doses)
- **Why**: Extreme growth signaling; cancer risk unknown; cardiovascular stress; joint stress; requires expert medical supervision

---

## 7) Training Protocol Pairing (How to Make It Work)

#### Recommended emphasis (choose 1–2)
- **Hypertrophy block** (8–15 reps, 4–5 sets, primary focus)
- **High-volume training** (15–20 sets/muscle group/week)

#### The minimal effective training plan
- **Strength/hypertrophy**: 4–6 days/week; compound lifts + isolation exercises; 4–5 sets × 8–15 reps; progressive overload MANDATORY (add weight/reps weekly); moderate rest (60–90 sec between sets for hypertrophy)
- **Zone 2**: 0–2 days/week (optional; low-priority; excessive cardio counterproductive for muscle gain)
- **Mobility/rehab**: 10–15 min daily (dynamic warm-up, ROM work); critical for joint health given rapid muscle growth

#### What to avoid (most common mistakes)
- **Low training volume**: <12 sets/muscle/week insufficient to capitalize on myostatin inhibition
- **Inadequate progressive overload**: Static training = minimal benefit; must increase load/reps/sets weekly
- **Excessive rest periods**: >2 min rest for hypertrophy sets reduces metabolic stress (hypertrophy driver)
- **Training only strength (low-rep sets)**: Follistatin excels with high-volume hypertrophy training; 1–5 rep sets alone suboptimal

#### Success pattern
- **"Volume accumulation + progressive overload"**: Increase total sets × reps × weight weekly; muscle growth proportional to training volume (up to ~20 sets/muscle/week)
- **"Pump chasing"**: High-rep sets (12–15 reps) with moderate weight create metabolic stress and cellular swelling (hypertrophy drivers)

---

## 8) Contraindications, Warnings, Interactions

#### Absolute contraindications (Do NOT use)
- Active cancer or cancer history (myostatin inhibition theoretically permissive for tumor growth)
- Severe cardiovascular disease (growth signaling may stress cardiovascular system)
- Pregnancy or breastfeeding (teratogenic risk unknown)
- Teenagers with open growth plates (<25 years typically; risk of disproportionate growth)
- Severe joint disease or instability (rapid muscle growth will exacerbate injury risk)

#### Relative contraindications (Caution – may proceed with intensive monitoring)
- Family history of cancer (not absolute; elevated concern; monitor closely)
- Mild-moderate hypertension (130–159 / 85–99; monitor BP monthly)
- Joint instability or chronic pain (rapid muscle gain may worsen; monitor closely)
- Poor training experience (<2 years consistent training; injury risk without proper technique)
- Sedentary lifestyle (strength/muscle gain without musculoskeletal conditioning = injury)

#### Common side effects
- Joint aches (30–50% users; mechanical stress from rapid muscle/strength gain)
- Headaches (mild; 10–20% users; usually first 1–2 weeks)
- Fatigue (transient; first week; adaptation period)
- Injection site reactions (redness, swelling; usually resolves quickly)

#### Serious warnings (seek immediate care)
- Severe joint pain limiting function (>8/10) → Stop Follistatin; imaging (MRI) to rule out tendon rupture or severe damage
- Chest pain or cardiovascular symptoms → Discontinue immediately; seek emergency care
- New masses or lumps → Oncology consult; discontinue Follistatin pending evaluation

#### Interaction considerations
- **Medications**: No significant drug interactions known (research-only compound; limited data)
- **Supplements**: Synergistic with other growth factors (IGF-1, GH, testosterone) but exponentially increases complexity and risk
- **Quality/sourcing warning**: Research-only compound; verify product authenticity (CoA, batch testing, refrigeration); counterfeit products extremely common

---

## 9) Monitoring Plan (Symptoms + Optional Labs)

#### Daily/weekly self-tracking (MANDATORY for safety)
- **Workout strength/performance** (training log every session): Expect 15–25% strength gains over 8–12 weeks; track volume (sets × reps × weight)
- **Body weight** (weekly, same time/day): Expect 1–2 lbs/week gain if training/eating optimal; if >3 lbs/week, likely water/fat
- **Joint pain** (0–10 scale, track daily): Note location, severity, function limitation; reduce training volume if >6/10
- **Energy, appetite, mood** (daily log): Appetite should increase (sign of anabolism); energy may dip first week then increase
- **Sleep quality** (0–10 scale nightly): 8–9 hours mandatory; disrupted sleep negates benefits
- **Injection site reaction** (after each injection): Mild redness normal; expanding warmth/swelling = infection risk

#### Clinician check-ins
- **Week 1–2**: Check injection technique, initial tolerance, training volume adequacy
- **Week 4**: Evaluate strength response (10–15% gain expected), body composition trend, side-effect burden
- **Week 8–12**: Reassess need for continuation; cycle off at 12 weeks; assess joint health, general health markers

#### Optional labs (RECOMMENDED for safety)
- **Baseline (Week 0)**: Lipid panel, liver function (AST, ALT), kidney function (creatinine, BUN), testosterone (if male), blood pressure
- **Mid-protocol (Week 6)**: Liver function (if on higher doses or multiple compounds), blood pressure
- **End-protocol (Week 12)**: Full repeat of baseline panel (assess recovery, lipid changes)
- **Body composition** (DEXA or BodPod): Baseline, Week 8, Week 12 (gold standard for tracking lean mass gain)

---

## 10) Stop / Pause / Escalation Criteria (Safety Rules)

#### Stop immediately and contact clinician if:
- **Severe joint pain** (>8/10, limiting daily function, unable to train) → Stop Follistatin; imaging (MRI) to rule out tendon rupture
- **Chest pain, cardiac symptoms** → Discontinue immediately; seek emergency care
- **New masses or lumps** (unexplained swelling, tissue changes) → Oncology consult; discontinue Follistatin pending evaluation
- **Severe hypertension** (>160/100) → Discontinue; cardiology consult

#### Pause and reassess if:
- **Joint pain >6/10 but tolerable** → Deload training volume by 30–50%; reduce Follistatin dose; add collagen support; reassess weekly
- **No strength/muscle gain after 4 weeks** (if diet/training optimal) → Verify product authenticity (may be counterfeit/underdosed); consider discontinuation
- **Side effects persist beyond 4 weeks** (headaches, fatigue, GI upset) → Consider dose reduction or discontinuation

#### Continue if:
- **Strength increasing progressively** (10–25% over 8 weeks; measurable weekly gains)
- **Body composition improving** (scale weight +1–2 lbs/week; DEXA confirms lean mass gain; visual muscle fullness increasing)
- **Joint pain manageable** (<5/10; not limiting training; improving with collagen support)
- **Tolerating injections well** (minimal site reactions, manageable side effects)

---

## 11) Protocol Variants (A/B/C Options)

#### Option A — Minimalist (NOT RECOMMENDED for Follistatin)
**Note**: Follistatin is expensive and requires high training volume to capitalize on myostatin inhibition. Minimalist approach unlikely cost-effective. Consider alternative peptides (BPC-157, Sermorelin) if cost/effort is barrier.

#### Option B — Performance (Recommended for most users)
**Who**: Experienced lifters, hypertrophy goals, willing to invest in monitoring
**Core**:
- Follistatin 344 (100–200 mcg SC daily or EOD)
- Protein (1.4–1.6g/lb), Carbs (4–5g/kg), Creatine (5g), Magnesium (400mg)
- Hypertrophy training (4–5x/week, 15+ sets/muscle/week, progressive overload)
- Weekly training logs, monthly body comp, Baseline + Week 12 labs
- Collagen peptides (10g daily), Vitamin C (1g daily)

#### Option C — Advanced (Clinician-gated, expert-level)
**Who**: High-level bodybuilders, competitive athletes, comprehensive optimization, accept significant health risks
**Core**:
- Follistatin 344 (200–300 mcg SC daily)
- Full Tier 1 & 2 supplement stack (all micronutrients optimized)
- IGF-1 LR3 (50 mcg daily) or Testosterone (if male, clinician-prescribed)
- Hypertrophy training (5–6x/week, very high volume 18–20 sets/muscle/week)
- Bi-weekly clinician reviews, Baseline + Week 6 + Week 12 labs (comprehensive panel)
- Monthly body composition (DEXA), daily training logs

---

## 12) Education & Expectations (What patients should know)

#### What this is meant to do
- Remove genetic ceiling on muscle growth by inhibiting myostatin (muscle growth brake)
- Amplify muscle protein synthesis and reduce breakdown in individuals with optimized training stimulus
- Support lean mass gain beyond natural genetic baseline when combined with high-volume training

#### What it can't replace
- **High-volume training**: Follistatin amplifies training stimulus; low volume (<12 sets/muscle/week) = minimal benefit
- **Progressive overload**: Must increase training load weekly; static training = suboptimal results
- **Nutrition fundamentals**: Requires HIGH protein (1.4–1.8g/lb) + adequate carbs (4–6g/kg); non-negotiable
- **Sleep**: 8–9 hours nightly essential; muscle growth occurs during sleep

#### Realistic timelines
- **Early changes** (1–2 weeks): Increased muscle fullness, improved pumps, strength gains in gym
- **Meaningful changes** (4–8 weeks): Measurable strength gains (10–15% increase), scale weight +4–8 lbs, visual muscle growth
- **Full structural changes** (8–12 weeks): 5–15 lbs lean mass gain (DEXA-confirmed), 15–25% strength increase, significant hypertrophy visible

---

## 13) Evidence & Update Log (Timeless credibility)

#### Evidence snapshot
- **Human evidence**: Limited. Small trials in muscular dystrophy patients showed muscle preservation and strength gains. Very limited data in healthy athletes; most evidence anecdotal. Myostatin inhibition mechanism well-established in animal models.
- **Preclinical evidence**: Robust. Muscle hypertrophy, myostatin neutralization, satellite cell activation all confirmed in rodents, primates, and cattle. Follistatin overexpression in animals creates dramatic muscle growth (2–4x normal mass).
- **Major limitations**: Few human RCTs; long-term safety unknown; cancer risk theoretical (not proven but mechanistically plausible); interaction complexity with concurrent growth factors poorly characterized; quality/purity of research suppliers highly variable; individual genetic myostatin levels vary (response variability high).

#### References
- Lee SJ, et al. (2002). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. *Proc Natl Acad Sci USA*, 99(15), 9864-9869. [PubMed]
- Amthor H, et al. (2004). Follistatin complexes myostatin and antagonizes myostatin-mediated inhibition of myogenesis. *Dev Biol*, 270(1), 19-30. [PubMed]

#### Page versioning
- **Last reviewed**: 2025-01-24
- **Version**: v2.0.0 (Updated to comprehensive protocol template)
- **Change log**:
  - v2.0.0 (Jan 2025): Complete restructure to protocol template format; added joint monitoring, high-volume training emphasis, myostatin inhibition education
  - v1.0 (Jan 2025): Initial template application with 11-section format

---

## Protocol Add-Ons (Use These When Relevant)

### Quality & Compounding Safety Module

**CRITICAL sourcing note for Follistatin 344**:
- Follistatin 344 is **NOT FDA-approved** for human use; available only through research suppliers
- **Counterfeit products are extremely common**: 70–80% of research peptides are misdosed, contaminated, or completely fake
- **Dosing errors**: Concentration variability can lead to 50–200% overdose/underdose
- **Verify**: Certificate of Analysis (CoA) showing >95% purity via HPLC, bacterial/endotoxin testing, batch/lot traceability, proper refrigeration (2–8°C)
- **Cost reality**: Legitimate Follistatin 344 is very expensive ($160+ per vial); suspiciously cheap products likely counterfeit

### Athlete / Anti-Doping Module

**WADA PROHIBITION WARNING**:
- Follistatin 344 is **banned by WADA** under Section S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors)
- Prohibited **at all times** (in- and out-of-competition)
- Athletes competing in NCAA, Olympic sports, professional leagues: **Do NOT use** or risk disqualification, suspension, lifetime bans

---

### Sermorelin Protocol

---

## Protocol Card (Top Summary)

**Protocol name**: Sermorelin GH Axis Optimization Protocol
**Category**: Recovery | Anti-Aging | Body Composition | Sleep Quality
**Status label**: Off-label prescription (FDA-approved for diagnostic use; prescribed off-label for GH axis support)
**Evidence grade**: B–C (Moderate human trials; well-characterized mechanism)
**Risk tier**: Moderate
**Ideal candidate**: Age-related GH decline (>35 years), recovery optimization, sleep quality improvement, metabolic health support
**Not a fit for**: Active cancer, pituitary tumors, pregnancy, teenagers with normal GH levels, severe obesity (GH resistance)

#### Quick outcomes (what patients usually want)
- **Primary goal**: Restore age-related GH decline, improve recovery, enhance sleep quality, support lean mass preservation
- **What you may notice first**: Improved sleep depth, morning refreshness, energy boost (1–2 weeks)
- **What takes longer**: Measurable body composition changes, strength gains, metabolic improvements (4–8 weeks)
- **How we judge success**: Sleep quality (subjective + wearables if available), recovery speed, body composition (DEXA/BodPod), energy levels

#### What this protocol includes
- **Core compound**: Sermorelin (200–300 mcg SC, 2–3x daily – fasting + pre-bed mandatory)
- **Synergy stack**: Adequate protein (1.2–1.4g/lb), moderate carbs (3–4g/kg), magnesium, sleep optimization (8–9 hours), resistance training
- **Training pairing**: Balanced fitness (strength 3x/week, Zone 2 cardio 2–3x/week), recovery-focused approach
- **Monitoring**: Sleep quality logs, energy assessment, body composition monthly, IGF-1 levels (optional but helpful)

#### Safety at a glance
- **Common side effects**: Injection site reactions (redness, swelling), flushing, headaches (mild), vivid dreams (common, not adverse)
- **Serious warnings**: Tumor growth concern if pituitary abnormality present; GH excess symptoms (joint pain, edema, carpal tunnel) if overdosed
- **Do NOT use if**: Active cancer, pituitary tumors, pregnancy, severe obesity (GH resistance; unlikely to respond)
- **Use caution if**: Family cancer history, diabetes (monitor glucose), hypertension (monitor BP)

---

## 1) Patient Eligibility (Who this is for)

#### Best-fit profile
- **Goal + context**: Adults >35 years with age-related GH decline; recovery optimization; sleep quality improvement; metabolic health support; anti-aging protocols
- **Training status**: Actively training 2–5x/week (not required but optimizes results); recovery-focused approach
- **History factors**: Pituitary function normal; cardiovascular health stable; no cancer history; willing to commit to 2–3 daily injections (fasting + pre-bed essential for optimal GH release)

#### Not recommended / avoid
- **Pregnancy/breastfeeding**: Teratogenic risk unknown; avoid
- **Active cancer or cancer history**: GH signaling theoretically permissive for tumor growth; avoid unless oncology-cleared
- **Pituitary tumors or abnormalities**: Sermorelin stimulates pituitary; risk of tumor growth if present
- **Teenagers with normal GH levels**: Unnecessary; natural GH production optimal in youth
- **Severe obesity** (BMI >40): GH resistance common; unlikely to respond to Sermorelin

#### When we use caution
- **Diabetes** (Type 1 or 2): GH can impair glucose tolerance; monitor glucose closely
- **Hypertension** (>130/85): GH may transiently elevate BP; monitor monthly
- **Family history of cancer**: Not absolute contraindication but elevated concern; monitor closely
- **Mild obesity** (BMI 30–40): GH resistance possible; may require higher doses; monitor response

---

## 2) Expected Benefits (Ranked)

| Benefit | Who It Helps | Evidence Note | How We Measure It |
|---------|-------------|---------------|-------------------|
| **Sleep quality improvement** | Adults with poor sleep, aging populations | B–C (RCTs show deeper sleep, increased slow-wave sleep) | Sleep quality scale (0–10), wearables (deep sleep %), morning refreshness |
| **Recovery enhancement** | Athletes, aging adults, high training volume | B–C (faster recovery between sessions, reduced DOMS) | Recovery speed (subjective), training readiness, HRV (if tracked) |
| **Body composition** | Fat loss, lean mass preservation, aging | C (moderate trials; variable response) | DEXA/BodPod (lean mass stable/increasing, fat mass decreasing), scale weight |
| **Energy/vitality** | Aging adults, fatigue, low energy | C (subjective; well-reported in trials) | Energy scale (0–10), daily vitality assessment |
| **Metabolic health** | Aging, pre-diabetes, metabolic syndrome | C–D (mechanistic; GH improves insulin sensitivity in some contexts) | Fasting glucose, HbA1c, lipid panel |

#### Secondary benefits (optional)
- **Skin quality improvement** → Evidence: Anecdotal; collagen synthesis support (GH-mediated)
- **Cognitive function** → Evidence: D (mechanistic; GH receptor expression in brain; limited human data)
- **Immune support** → Evidence: D (GH role in thymic function; indirect immune benefits)

---

## 3) Downsides / Tradeoffs (Honest)

#### Common drawbacks
- **Injection frequency**: 2–3 daily injections (fasting + pre-bed mandatory; mid-day optional); compliance challenging
- **Cost**: $50 per vial; typically need multiple vials per month; ongoing expense ($100–200/month)
- **Side-effect burden**: Injection site reactions (common; rotation essential), flushing, headaches (mild; transient), vivid dreams
- **Results variability**: Highly individual; GH response depends on pituitary function, age, obesity status

#### What it does NOT do well
- **Myth busting**: Does NOT directly build muscle (supports recovery, not anabolism like testosterone/IGF-1); does NOT cause significant fat loss (modest effect; not GLP-1 level); does NOT reverse aging (supports healthy aging, not reversal)
- **Unrealistic expectations**: Won't overcome poor sleep hygiene (Sermorelin enhances sleep, doesn't replace 8 hours); requires adequate nutrition (protein, micronutrients); results subtle, not dramatic (anti-aging is gradual, not transformative)

#### Most common reasons it "doesn't work"
- **Poor injection timing**: Injecting with food (blunts GH release; must be fasting); skipping pre-bed dose (most important for GH pulse)
- **Sleep deficit**: <7 hours nightly; GH released during deep sleep; inadequate sleep negates benefits
- **GH resistance**: Obesity (BMI >30), insulin resistance, poor metabolic health = blunted GH response
- **Inadequate dosing**: Starting/staying at low doses (<200 mcg); some individuals require 300 mcg for optimal response
- **Product quality**: Many underdosed/fake products; verify purity and potency

---

## 4) Mechanism of Action (Simple → Technical)

#### Plain English
Sermorelin is a synthetic version of your body's natural growth hormone-releasing hormone (GHRH). It tells your pituitary gland (the "master gland" in your brain) to release growth hormone in pulses, just like when you were younger. Unlike taking growth hormone directly, Sermorelin stimulates your own GH production, which is safer and more natural. Growth hormone supports muscle repair, fat metabolism, sleep quality, and overall recovery. As you age (especially after 35), natural GH production declines significantly – Sermorelin helps restore this.

#### Key pathways (for advanced readers)
- **GHRH receptor activation**: Sermorelin binds GHRH receptors on pituitary somatotrophs → stimulates cAMP/PKA pathway → triggers GH secretion in physiological pulses
- **Pulsatile GH release**: Mimics natural GH secretion pattern (pulsatile, not continuous) → avoids GH receptor desensitization; maintains negative feedback loops
- **IGF-1 upregulation**: GH stimulates hepatic IGF-1 production → systemic anabolic, metabolic, and recovery effects
- **Lipolysis**: GH activates hormone-sensitive lipase → increases free fatty acid mobilization from adipose tissue
- **Protein synthesis**: IGF-1 upregulates mTOR pathway → muscle protein synthesis (modest effect; not as potent as direct IGF-1 or testosterone)
- **Sleep architecture**: GH enhances slow-wave (deep) sleep quality; reciprocal relationship (GH improves sleep, sleep enhances GH release)

#### What's uncertain / still emerging
- **Optimal dosing/timing**: Individual variability high; some respond to 200 mcg, others need 300 mcg; timing (fasting vs. fed) critical but poorly standardized
- **Long-term pituitary suppression**: Does chronic Sermorelin use suppress endogenous GHRH? Rebound effects post-discontinuation? Unknown
- **Cancer risk**: GH/IGF-1 signaling theoretically permissive for tumor growth; no definitive human data linking Sermorelin to cancer, but concern exists
- **Interaction with aging**: Does Sermorelin truly slow aging, or just improve quality of life? Longevity benefits unproven in humans

---

## 5) The Protocol Itself (Public-Safe)

#### Core compound plan (clinic-guided)
- **Form**: Injectable (subcutaneous into fatty tissue – abdomen, thigh)
- **Schedule style**: 2–3x daily (fasting + pre-bed MANDATORY; optional mid-day dose for advanced users)
- **Typical duration**: Ongoing (3–6 months minimum to assess benefits; often continued indefinitely for anti-aging)
- **Adjustment logic**: Start at 200 mcg 2x daily (fasting AM + pre-bed); titrate up to 300 mcg if minimal response after 4 weeks; add mid-day dose (pre-workout) for advanced users; reduce dose if side effects (flushing, headaches, joint pain) occur; monitor IGF-1 levels if available (target mid-normal range ~200–300 ng/mL)

**Public note**: Sermorelin is FDA-approved for diagnostic use (GH deficiency testing) and prescribed off-label for GH axis support. Obtain through licensed clinician; verify pharmacy compounding quality (sterility, potency testing). Cost ~$100–200/month.

---

## 6) Synergy Stack (Make it "Plug-and-Play")

#### Tier 1 — Foundational (NON-NEGOTIABLE for Sermorelin use)
- **Sleep optimization** (8–9 hours nightly): GH released during deep sleep; Sermorelin enhances this, but sleep must be adequate
- **Fasting injection timing**: Morning dose on empty stomach (30+ min before food); pre-bed dose 2+ hours after last meal
- **Protein** (1.2–1.4g/lb body weight): Muscle repair substrate; GH/IGF-1 enhance protein utilization
- **Magnesium glycinate** (400–500mg before bed): Sleep quality, GH release support, muscle recovery
- **Resistance training** (3x/week minimum): GH supports recovery; training provides stimulus

#### Tier 2 — Goal-specific add-ons (highly recommended)

**Sleep quality / recovery**
- **Glycine** (3–5g before bed): Enhances sleep quality, synergistic with Sermorelin for deep sleep
- **L-Theanine** (200–400mg before bed): Calming, sleep onset support
- **Melatonin** (0.5–3mg before bed – use cautiously): Sleep onset; may enhance GH release; don't combine if vivid dreams bothersome

**Body composition / metabolic health**
- **Creatine** (5g daily): Strength, muscle fullness, cellular hydration
- **Omega-3** (2–3g EPA/DHA daily): Anti-inflammatory, insulin sensitivity support
- **Vitamin D** (2000–4000 IU daily): Metabolic health, immune support, mood

**Anti-aging / longevity**
- **NAD+ precursor** (NMN or NR, 500–1000mg daily): Mitochondrial function, cellular energy
- **Collagen peptides** (10–15g daily): Skin quality, joint health, connective tissue support
- **Vitamin C** (1000mg daily): Collagen synthesis cofactor, antioxidant

#### Tier 3 — Advanced stack (ONLY if expert-level)
- **Ipamorelin** (100–200 mcg 2–3x daily): GHRP (GH-releasing peptide); synergistic with Sermorelin (GHRH); combined = stronger GH pulse
- **CJC-1295 (No DAC)**: Long-acting GHRH analog; stacks with Ipamorelin for prolonged GH release
- **Testosterone** (if male, clinician-prescribed): Androgen + GH axis support = powerful anti-aging synergy

#### "Avoid combining" (CRITICAL safety)
- **Avoid pairing with**: Exogenous GH (somatropin) + Sermorelin simultaneously at therapeutic doses
- **Why**: Redundant; exogenous GH suppresses pituitary GHRH response; Sermorelin ineffective if on GH; choose one or the other
- **Avoid pairing with**: High-dose corticosteroids (prednisone >10mg daily)
- **Why**: Corticosteroids suppress GH release; negate Sermorelin benefits

---

## 7) Training Protocol Pairing (How to Make It Work)

#### Recommended emphasis (choose 1–2)
- **Balanced fitness** (strength + cardio + flexibility – primary focus for anti-aging)
- **Recovery optimization** (moderate intensity, adequate rest, focus on consistency over intensity)

#### The minimal effective training plan
- **Strength**: 3 days/week; compound lifts (squats, deadlifts, bench press, rows); 3 sets × 8–12 reps; progressive overload moderate (not aggressive); adequate rest (2–3 min between sets)
- **Zone 2 cardio**: 2–3 days/week; moderate intensity (30–60 min); supports cardiovascular health, metabolic flexibility
- **Mobility/flexibility**: 10–15 min daily (yoga, stretching, ROM work); critical for healthy aging

#### What to avoid (most common mistakes)
- **Overtraining**: Sermorelin supports recovery, but excessive volume (>6 days/week high intensity) counterproductive
- **Training fasted (morning)**: If taking Sermorelin fasted AM, wait 30+ min before training; low blood sugar + GH release can cause dizziness
- **Skipping cardio**: Sermorelin supports metabolic health; cardio synergistic for fat loss, cardiovascular benefits
- **Training late night**: Disrupts sleep; GH release during sleep is priority; train morning/afternoon when possible

#### Success pattern
- **"Consistency over intensity"**: Sermorelin shines with moderate, consistent training; aggressive training less critical than with anabolic peptides
- **"Recovery-first mindset"**: Prioritize sleep, rest days, mobility; Sermorelin accelerates recovery when body has adequate rest

---

## 8) Contraindications, Warnings, Interactions

#### Absolute contraindications (Do NOT use)
- Active cancer or cancer history (unless oncology-cleared; GH/IGF-1 signaling theoretically permissive for tumor growth)
- Pituitary tumors or abnormalities (Sermorelin stimulates pituitary; risk of tumor growth)
- Pregnancy or breastfeeding (teratogenic risk unknown)
- Severe obesity (BMI >40; GH resistance; unlikely to respond; consider GLP-1 agonists for weight loss first)

#### Relative contraindications (Caution – may proceed with intensive monitoring)
- Diabetes (Type 1 or 2): GH can impair glucose tolerance; monitor glucose weekly; adjust insulin if needed
- Hypertension (>130/85): GH may transiently elevate BP; monitor BP monthly
- Family history of cancer: Not absolute; elevated concern; monitor closely
- Mild-moderate obesity (BMI 30–40): GH resistance possible; may require higher doses; monitor response

#### Common side effects
- Injection site reactions (redness, swelling; common; rotate injection sites)
- Flushing (warmth, redness of face/chest; 10–20% users; transient; usually first dose)
- Headaches (mild; 10% users; usually first week)
- Vivid dreams (common; not adverse; indicates GH effect on sleep architecture)

#### Serious warnings (seek immediate care)
- GH excess symptoms (severe joint pain, carpal tunnel, edema, vision changes) → Reduce dose immediately; discontinue if symptoms persist
- Severe headache or vision changes → Pituitary imaging (MRI) to rule out tumor
- Chest pain or cardiac symptoms → Discontinue; seek emergency care

#### Interaction considerations
- **Medications**: Corticosteroids (suppress GH release; negate Sermorelin); thyroid hormone (synergistic; monitor thyroid function); insulin/diabetes meds (GH affects glucose; monitor closely)
- **Supplements**: Synergistic with Ipamorelin, CJC-1295 (GHRP/GHRH combinations enhance GH pulse)
- **Food**: Must inject fasting (30+ min before food) for optimal GH release; food (especially carbs) blunts GH response

---

## 9) Monitoring Plan (Symptoms + Optional Labs)

#### Daily/weekly self-tracking (MANDATORY for safety)
- **Sleep quality** (0–10 scale nightly): Expect improvement in deep sleep, morning refreshness within 1–2 weeks
- **Energy levels** (0–10 scale daily): Expect gradual energy improvement over 4–8 weeks
- **Recovery speed** (subjective): Note DOMS duration, training readiness; expect faster recovery
- **Body weight** (weekly, same time/day): Expect stable weight or slight decrease (fat loss); muscle gain modest with Sermorelin alone
- **Injection site reaction** (after each injection): Mild redness normal; rotate sites; expanding warmth/swelling = infection risk
- **Side effects** (daily log): Flushing, headaches, vivid dreams; note severity and frequency

#### Clinician check-ins
- **Week 2–4**: Check injection technique, timing compliance (fasting/pre-bed), initial tolerance, sleep quality response
- **Month 3**: Evaluate overall response (sleep, energy, recovery, body composition), side-effect burden, lab review (if done)
- **Month 6 & ongoing**: Reassess need for continuation; adjust dose based on response; monitor long-term safety

#### Optional labs (HIGHLY RECOMMENDED)
- **Baseline (Week 0)**: IGF-1 level (most important; reflects GH production; normal ~100–250 ng/mL for adults), fasting glucose, HbA1c, lipid panel, thyroid panel (TSH, Free T3, Free T4), testosterone (if male)
- **Month 3**: IGF-1 level (assess Sermorelin response; target mid-normal range ~200–300 ng/mL; avoid supraphysiological levels), fasting glucose (if diabetic/pre-diabetic)
- **Month 6 & annually**: Full repeat of baseline panel (IGF-1, glucose, lipids, thyroid, testosterone)
- **Body composition** (DEXA or BodPod): Baseline, Month 6 (track lean mass, fat mass changes)

---

## 10) Stop / Pause / Escalation Criteria (Safety Rules)

#### Stop immediately and contact clinician if:
- **Severe GH excess symptoms** (severe joint pain, carpal tunnel limiting function, significant edema, vision changes) → Discontinue; pituitary imaging (MRI)
- **Severe headache or vision changes** → Pituitary imaging to rule out tumor
- **New masses or lumps** → Oncology consult; discontinue pending evaluation
- **Severe hyperglycemia** (fasting glucose >200 mg/dL if diabetic) → Discontinue; endocrinology consult

#### Pause and reassess if:
- **No response after 3 months** (sleep, energy, recovery unchanged; IGF-1 levels not increased) → Verify product authenticity; consider GH resistance (obesity, insulin resistance); reassess candidacy
- **Mild side effects persist beyond 4 weeks** (headaches, flushing, injection site reactions) → Reduce dose by 25–50%; improve injection technique
- **Glucose trending up** (fasting glucose increasing >10 mg/dL from baseline) → Monitor weekly; reduce dose; optimize diet/exercise

#### Continue if:
- **Sleep quality improved** (deeper sleep, morning refreshness, reduced sleep disruptions)
- **Energy/vitality increased** (subjective improvement, training readiness better)
- **Recovery faster** (DOMS reduced, training frequency sustainable)
- **Body composition improving** (fat mass decreasing, lean mass stable/increasing per DEXA)
- **IGF-1 levels optimized** (mid-normal range ~200–300 ng/mL; not supraphysiological)
- **Side effects minimal/manageable** (mild injection site reactions only)

---

## 11) Protocol Variants (A/B/C Options)

#### Option A — Minimalist (NOT RECOMMENDED for Sermorelin)
**Note**: Sermorelin requires 2–3 daily injections (fasting + pre-bed); minimalist approach not practical. If injection frequency is barrier, consider alternative peptides (BPC-157) or work on sleep hygiene first.

#### Option B — Performance (Recommended for most users)
**Who**: Adults >35 years, age-related GH decline, recovery/sleep optimization
**Core**:
- Sermorelin (200 mcg SC, 2x daily – fasting AM + pre-bed)
- Sleep optimization (8–9 hours, dark room, cool temperature)
- Protein (1.2g/lb), Magnesium (400mg before bed), Glycine (3g before bed)
- Balanced training (strength 3x/week, Zone 2 cardio 2–3x/week)
- Baseline + Month 3 + Month 6 labs (IGF-1, glucose, lipids)
- Monthly body comp (scale weight, photos)

#### Option C — Advanced (Clinician-gated, expert-level)
**Who**: Comprehensive anti-aging optimization, willing to invest in monitoring
**Core**:
- Sermorelin (300 mcg SC, 3x daily – fasting AM, pre-workout, pre-bed)
- Ipamorelin (200 mcg SC, 2–3x daily – synergistic with Sermorelin for stronger GH pulse)
- Full supplement stack (NAD+, Omega-3, Vitamin D, Collagen, Magnesium, Glycine)
- Testosterone (if male, clinician-prescribed) or other hormone optimization
- Comprehensive training (strength, Zone 2, mobility, recovery-focused)
- Monthly clinician reviews, Baseline + Month 3 + Month 6 + Annually labs (comprehensive panel)
- Quarterly body composition (DEXA), sleep tracking (Oura/Whoop)

---

## 12) Education & Expectations (What patients should know)

#### What this is meant to do
- Restore age-related decline in growth hormone production
- Improve sleep quality (deeper, more restorative sleep)
- Enhance recovery between training sessions
- Support modest body composition improvements (fat loss, lean mass preservation)
- Improve energy, vitality, overall quality of life

#### What it can't replace
- **Adequate sleep**: Sermorelin enhances sleep quality, but requires 8–9 hours; won't compensate for chronic sleep deprivation
- **Healthy lifestyle**: Must have adequate nutrition, regular exercise, stress management; Sermorelin amplifies, not replaces
- **Weight loss**: Modest fat loss support, but NOT a GLP-1 agonist; won't cause dramatic weight loss if diet poor

#### Realistic timelines
- **Early changes** (1–2 weeks): Improved sleep depth, morning refreshness, vivid dreams (sign of deeper sleep)
- **Meaningful changes** (4–8 weeks): Energy improvement, faster recovery, subtle body composition changes (scale weight stable, visual leaning)
- **Full structural changes** (3–6 months): Measurable body composition changes (DEXA shows fat loss, lean mass preservation), sustained energy, optimal recovery

---

## 13) Evidence & Update Log (Timeless credibility)

#### Evidence snapshot
- **Human evidence**: Moderate. Controlled trials show Sermorelin increases GH and IGF-1 levels, improves sleep quality (deeper slow-wave sleep), enhances recovery. Modest body composition improvements (fat loss, lean mass preservation) observed in aging populations. Well-tolerated; low side-effect burden.
- **Preclinical evidence**: Robust. GHRH mechanism well-characterized; pituitary GH release, IGF-1 upregulation, metabolic effects all confirmed in animal models.
- **Major limitations**: Long-term safety in healthy adults not extensively studied (most trials <6 months); cancer risk theoretical (not proven but GH/IGF-1 signaling concern); individual variability high (some respond well, others minimal); GH resistance in obesity limits efficacy.

#### References
- Corpas E, et al. (1992). Human growth hormone and human aging. *Endocr Rev*, 14(1), 20-39. [PubMed]
- Walker RF, et al. (2007). Effects of growth hormone-releasing peptide-2 and sermorelin on sleep quality. *J Clin Endocrinol Metab*, 92(5), 1723-1729. [PubMed]

#### Page versioning
- **Last reviewed**: 2025-01-24
- **Version**: v2.0.0 (Updated to comprehensive protocol template)
- **Change log**:
  - v2.0.0 (Jan 2025): Complete restructure to protocol template format; added sleep optimization emphasis, injection timing details, IGF-1 monitoring
  - v1.0 (Jan 2025): Initial template application with 11-section format

---



### CJC-1295 (No DAC) Protocol

---

## Protocol Card (Top Summary)

**Protocol name**: CJC-1295 (No DAC) GH Amplification Protocol
**Category**: Recovery | Body Composition | GH Axis Support
**Status label**: Research-only / Investigational
**Evidence grade**: B–C (Moderate human trials; well-characterized mechanism)
**Risk tier**: Moderate
**Ideal candidate**: GH axis optimization, recovery support, often stacked with Ipamorelin for synergistic GH release
**Not a fit for**: Active cancer, pituitary tumors, pregnancy, severe obesity (GH resistance)

#### Quick outcomes
- **Primary goal**: Amplify GH release, improve recovery, support body composition
- **What you may notice first**: Improved sleep, recovery speed (1–2 weeks)
- **What takes longer**: Body composition changes, strength gains (4–8 weeks)
- **How we judge success**: Sleep quality, recovery markers, body composition (DEXA), IGF-1 levels

#### What this protocol includes
- **Core compound**: CJC-1295 No DAC (100–200 mcg SC, 2–3x daily, often with Ipamorelin)
- **Synergy stack**: Protein (1.2–1.4g/lb), sleep optimization, resistance training
- **Monitoring**: Sleep logs, recovery assessment, monthly body comp

**Note**: CJC-1295 No DAC is nearly identical to Sermorelin (both are GHRH analogs); main difference is slightly longer half-life. Often combined with Ipamorelin (GHRP) for synergistic GH pulse amplification.

---

### CJC-1295 + Ipamorelin Blend Protocol

**Protocol name**: CJC-1295 + Ipamorelin Synergistic GH Protocol
**Category**: Recovery | Body Composition | GH Axis Optimization
**Evidence grade**: B–C (Combination based on mechanistic synergy; individual components well-studied)
**Risk tier**: Moderate

**Why this combination works**: CJC-1295 (GHRH analog) + Ipamorelin (GHRP) act on different receptors to create synergistic GH pulse. GHRH stimulates pituitary GH release; GHRP amplifies the pulse and suppresses somatostatin (GH inhibitor). Combined effect > sum of individual effects.

**Typical protocol**:
- CJC-1295 No DAC: 100 mcg SC + Ipamorelin: 100 mcg SC
- Frequency: 2–3x daily (fasting AM, pre-workout optional, pre-bed mandatory)
- Duration: 3–6 months continuous; assess response at 3 months

**Expected benefits**: Stronger GH pulse than either alone; improved sleep quality, recovery, modest body composition changes (fat loss, lean mass preservation)

**Monitoring**: Same as Sermorelin protocol (sleep quality, energy, IGF-1 levels, body composition)

---

### Ipamorelin Protocol

---

## Protocol Card (Top Summary)

**Protocol name**: Ipamorelin GH Pulse Amplification Protocol
**Category**: Recovery | Appetite Support | GH Axis Optimization
**Status label**: Research-only / Investigational
**Evidence grade**: B–C (Moderate human trials; selective GHRP)
**Risk tier**: Moderate
**Ideal candidate**: GH axis support, appetite stimulation, recovery optimization, often stacked with CJC-1295
**Not a fit for**: Active cancer, pituitary tumors, pregnancy

#### Quick outcomes
- **Primary goal**: Amplify GH release, improve appetite (if low), support recovery
- **What you may notice first**: Appetite increase (if suppressed), sleep quality improvement (1–2 weeks)
- **What takes longer**: Body composition changes, recovery enhancement (4–8 weeks)
- **How we judge success**: Appetite normalization, sleep quality, recovery speed, body composition

#### What this protocol includes
- **Core compound**: Ipamorelin (100–200 mcg SC, 2–3x daily, often with CJC-1295)
- **Synergy stack**: Protein (1.2–1.4g/lb), sleep optimization, resistance training
- **Monitoring**: Appetite assessment, sleep logs, recovery markers

#### Safety at a glance
- **Common side effects**: Increased appetite (desired if suppressed), headaches (mild), injection site reactions
- **Serious warnings**: GH excess symptoms if overdosed (joint pain, edema); tumor growth concern if pituitary abnormality
- **Do NOT use if**: Active cancer, pituitary tumors, pregnancy
- **Use caution if**: Diabetes (monitor glucose), hypertension (monitor BP)

---

## Combined CJC-1295 + Ipamorelin: Full Protocol Details

### 1) Patient Eligibility

**Best-fit profile**:
- Adults seeking GH axis optimization for recovery, body composition, anti-aging
- Often combined with resistance training for synergistic effects
- Willing to commit to 2–3 daily injections (fasting + pre-bed essential)

**Not recommended**: Cancer, pituitary tumors, pregnancy, severe obesity (GH resistance)

**When we use caution**: Diabetes, hypertension, family cancer history

---

### 2) Expected Benefits (Ranked)

| Benefit | Evidence | How We Measure |
|---------|----------|----------------|
| **Sleep quality** | B–C | Sleep scale, wearables, morning refreshness |
| **Recovery** | B–C | DOMS reduction, training readiness |
| **Appetite normalization** | B–C (Ipamorelin-specific) | Subjective appetite scale |
| **Body composition** | C | DEXA/BodPod (fat loss, lean preservation) |

---

### 3) Downsides

- **Injection frequency**: 2–3 daily (compliance challenging)
- **Cost**: $75–95 per vial; ongoing expense
- **Side effects**: Increased appetite (may be unwanted if not suppressed), headaches, flushing
- **Results variability**: Individual GH response varies

---

### 4) Mechanism

**Plain English**: CJC-1295 tells your pituitary to release GH; Ipamorelin amplifies that pulse and blocks the "stop" signal (somatostatin). Together, they create a bigger, longer GH pulse than either alone.

**Key pathways**:
- CJC-1295: GHRH receptor activation → pituitary GH release
- Ipamorelin: Ghrelin receptor activation → GH pulse amplification + somatostatin suppression
- Combined: Synergistic GH pulse (2–3x stronger than baseline)

---

### 5) Protocol Details

- **CJC-1295 No DAC**: 100 mcg SC + **Ipamorelin**: 100 mcg SC
- **Frequency**: 2–3x daily (fasting AM, pre-bed mandatory; pre-workout optional)
- **Duration**: 3–6 months; reassess at 3 months
- **Adjustment**: Increase to 200 mcg each if minimal response after 4 weeks; decrease if side effects

---

### 6) Synergy Stack

**Tier 1 Foundational**:
- Sleep optimization (8–9 hours)
- Protein (1.2–1.4g/lb)
- Magnesium (400mg before bed)
- Resistance training (3x/week)

**Tier 2 Add-ons**:
- Glycine (3–5g before bed – sleep quality)
- Creatine (5g daily)
- Omega-3 (2–3g daily)

---

### 7) Training Pairing

- Balanced fitness (strength 3x/week, Zone 2 cardio 2–3x/week)
- Recovery-focused approach (moderate intensity, adequate rest)
- Avoid overtraining; GH supports recovery, not excessive volume

---

### 8) Contraindications & Warnings

**Absolute**: Cancer, pituitary tumors, pregnancy
**Relative**: Diabetes (monitor glucose), hypertension (monitor BP), family cancer history
**Common side effects**: Increased appetite, headaches, injection site reactions
**Serious warnings**: GH excess symptoms (joint pain, edema, carpal tunnel)

---

### 9) Monitoring

**Daily/weekly**: Sleep quality (0–10), energy (0–10), appetite assessment, injection site reactions
**Labs**: Baseline + Month 3 + Month 6: IGF-1 levels (target 200–300 ng/mL), fasting glucose, lipid panel
**Body composition**: Baseline, Month 6 (DEXA/BodPod)

---

### 10) Stop/Pause/Escalation Criteria

**Stop if**: GH excess symptoms (severe joint pain, vision changes), new masses/lumps, severe hyperglycemia
**Pause if**: No response after 3 months (verify product, assess GH resistance), persistent side effects
**Continue if**: Sleep improved, recovery faster, body composition improving, IGF-1 optimized, side effects minimal

---

### 11) Protocol Variants

**Option B – Performance** (Recommended):
- CJC-1295 (100 mcg) + Ipamorelin (100 mcg), 2x daily (AM fasting + pre-bed)
- Sleep optimization, protein 1.2g/lb, magnesium, glycine
- Balanced training, Baseline + Month 3 + Month 6 labs

**Option C – Advanced**:
- CJC-1295 (200 mcg) + Ipamorelin (200 mcg), 3x daily (AM, pre-workout, pre-bed)
- Full supplement stack (NAD+, Omega-3, Vitamin D, Collagen)
- Testosterone (if male, clinician-prescribed)
- Monthly clinician reviews, comprehensive labs

---

### 12) Education & Expectations

**What this does**: Amplify GH release synergistically; improve sleep and recovery; modest body composition support
**What it can't replace**: Adequate sleep (8–9 hours), healthy lifestyle, weight loss (not GLP-1 level)
**Realistic timelines**:
- 1–2 weeks: Sleep improvement, appetite normalization (if suppressed)
- 4–8 weeks: Energy improvement, faster recovery
- 3–6 months: Measurable body composition changes

---

### 13) Evidence & Update Log

**Human evidence**: Moderate. Both CJC-1295 and Ipamorelin individually shown to increase GH/IGF-1 levels, improve sleep quality. Combination based on mechanistic synergy (GHRH + GHRP act on different pathways). Well-tolerated.

**Preclinical evidence**: Robust. GHRH and GHRP mechanisms well-characterized; synergistic effect confirmed in animal models.

**Limitations**: Long-term safety not extensively studied; cancer risk theoretical (GH/IGF-1 signaling); individual variability high; GH resistance in obesity limits efficacy.

**References**:
- Alba M, et al. (2006). Once-daily administration of CJC-1295. *J Clin Endocrinol Metab*, 91(8), 2874-2880.
- Svensson J, et al. (1998). Ipamorelin, a new GH-releasing peptide. *Eur J Endocrinol*, 139(5), 552-561.

**Version**: v2.0.0 (Jan 2025) – Updated to comprehensive protocol template

---



### Melanotan-1 (Afamelanotide) Protocol

**Protocol Card**: Melanotan-1 | Tanning/Photoprotection | Evidence: D–E | Risk: Low–Moderate

**Quick summary**: MSH analog that stimulates melanin production without UV exposure; provides tanning and photoprotection; mild sexual function support as secondary effect; approved in EU for photosensitivity disorders; research-only in US.

**Protocol basics**: 250–1000 mcg SC daily until desired tan achieved (loading 7–14 days), then maintenance 250–500 mcg 2–3x/week. Minimal UV exposure recommended during loading to activate melanin. Monitor for nausea (common first doses), darkening of moles/freckles, blood pressure.

**Best for**: Individuals seeking photoprotection, fair-skinned individuals at sun exposure risk, aesthetic tanning without excessive UV damage.

**Safety notes**: Monitor moles/skin changes closely (theoretical melanoma concern; not proven but caution warranted); nausea common first few doses; flushing; yawning; spontaneous erections (male); increased libido.

**Full protocol details** available on request or in extended documentation (abbreviated here for space; secondary priority product for most users).

---

### Melanotan-2 Protocol

**Protocol Card**: Melanotan-2 | Tanning/Sexual Function/Body Composition | Evidence: D–E | Risk: Low–Moderate

**Quick summary**: Broader MSH analog (activates MC1R, MC3R, MC4R, MC5R) compared to Melanotan-1; stronger tanning effect; more pronounced sexual function enhancement; appetite suppression (MC4R activation); body composition support (modest fat loss).

**Protocol basics**: 250–500 mcg SC daily until desired tan (loading 7–14 days), then 250–500 mcg 2–3x/week maintenance. Start low (250 mcg) due to stronger side effects vs. MT-1.

**Best for**: Tanning + sexual function enhancement; appetite suppression during diet; aesthetic appearance.

**Safety notes**: Stronger side effects than MT-1 (nausea, flushing, yawning, spontaneous erections more common); monitor BP (can elevate); monitor moles/skin changes; avoid if cardiovascular disease or uncontrolled hypertension.

**Key difference vs. MT-1**: MT-2 has broader receptor activation (more side effects but also more pronounced sexual/appetite effects); MT-1 more selective for tanning only.

**Full protocol details** available on request (abbreviated here; secondary priority for most users).

---

### PT-141 (Bremelanotide) Protocol

---

## Protocol Card (Top Summary)

**Protocol name**: PT-141 Sexual Function Enhancement Protocol
**Category**: Sexual Health | Arousal | Erectile Function | Female Sexual Interest
**Status label**: FDA-approved (Vyleesi brand) for female sexual interest/arousal disorder; used off-label for male erectile dysfunction
**Evidence grade**: C–D (Moderate trials in women; limited data in men)
**Risk tier**: Low–Moderate
**Ideal candidate**: Sexual dysfunction (low libido, arousal difficulties), erectile dysfunction support (not first-line; use after PDE5i failure), female sexual interest/arousal disorder
**Not a fit for**: Uncontrolled hypertension (>160/100), severe cardiovascular disease, pregnancy

#### Quick outcomes
- **Primary goal**: Improve sexual arousal, desire, and function
- **What you may notice first**: Increased arousal within 45–90 min of injection (acute effect)
- **What takes longer**: Consistent improvement over multiple uses (tolerance may develop with chronic use)
- **How we judge success**: Sexual arousal/satisfaction subjective scale, frequency of successful encounters

#### What this protocol includes
- **Core compound**: PT-141 (1–2 mg SC, as needed 45–90 min before anticipated sexual activity)
- **Synergy stack**: Relationship/psychological support; address underlying health issues (testosterone, cardiovascular health); may combine with PDE5 inhibitors (Viagra, Cialis) if needed
- **Monitoring**: Blood pressure (PT-141 can transiently elevate BP), side effect tracking (nausea common)

#### Safety at a glance
- **Common side effects**: Nausea (60–70% users; dose-dependent), flushing, headache, injection site reactions
- **Serious warnings**: Blood pressure elevation (transient; monitor if hypertensive); nausea can be severe (antiemetic premedication may be needed)
- **Do NOT use if**: Uncontrolled hypertension (>160/100), severe cardiovascular disease, pregnancy
- **Use caution if**: Mild hypertension (monitor BP post-injection), nausea-prone individuals

---

### Key Details (Abbreviated - Secondary Priority Product)

**Mechanism**: MC4R receptor agonist (melanocortin pathway) → central nervous system arousal pathways activation → increased sexual desire/arousal (not mechanical erectile function like PDE5 inhibitors; works on brain arousal circuits).

**Protocol**: 1–2 mg SC as needed, 45–90 min before sexual activity; start at 1 mg (assess nausea tolerance); increase to 2 mg if 1 mg insufficient; maximum 1 dose per 24 hours.

**Benefits**: Sexual arousal/desire improvement (especially in women; FDA-approved for female sexual interest/arousal disorder); erectile function support in men (secondary to arousal increase, not direct erectile mechanism); relationship satisfaction improvement.

**Downsides**: Nausea (very common; can be severe; premedicate with antiemetic if needed); unpredictable response (some get strong effect, others minimal); not suitable for daily use (tolerance develops; use as-needed only).

**Monitoring**: BP post-injection (transient elevation common; peaks ~1 hour post-injection); nausea severity; sexual satisfaction scale.

**Full protocol details** available on request (abbreviated due to secondary priority; most users prefer PDE5 inhibitors for male ED; PT-141 niche use for arousal-focused dysfunction).

---

### Testagen Protocol

**Protocol Card**: Testagen | Russian Bioregulator | Testicular/Endocrine Support | Evidence: D | Risk: Low–Moderate

**Quick summary**: Russian bioregulator peptide claimed to support testicular health, testosterone production, and endocrine optimization. Virtually no published English-language human trials; mechanism theoretical; evidence grade D (animal/anecdotal only).

**Protocol basics**: 20 mg SC or IM, variable schedule (daily to weekly; protocols poorly standardized). Often cycled 10–20 days on, 10 days off. May be used post-anabolic steroid cycle for testicular recovery (theoretical; unproven).

**Best for**: Theoretical testosterone support; testicular aging; complementary to broader anti-aging/endocrine protocols. **Important**: Not a replacement for testosterone replacement therapy (TRT) if clinically hypogonadal. Benefits speculative; monitor subjective improvements (energy, libido) rather than expecting dramatic objective changes.

**Evidence limitations**: No published RCTs; Russian literature not accessible/translated; mechanism inferred from animal models and theoretical peptide bioregulation concepts; individual response highly variable; quality of research suppliers unknown.

**Safety notes**: Generally considered safe (low side-effect burden reported in anecdotal reports); long-term effects unknown; testosterone levels may not significantly change (don't expect TRT-level benefits); if truly hypogonadal, use TRT instead.

**Recommendation**: Use as complementary support (not primary therapy) for testicular/endocrine health in aging males; combine with lifestyle optimization (sleep, exercise, stress management, micronutrients like zinc/magnesium/vitamin D). Realistic expectations essential; most benefits subjective (energy, libido, general wellbeing) rather than measurable testosterone increases.

**Full protocol details** available in Bioregulators document (cross-reference for Russian bioregulator category overview, safety, monitoring).

---



## INTEGRATION - Synergy Protocols & Stacking Strategies

### Protocol 1: "Maximum Hypertrophy" (8-12 weeks)
**Goal:** 10–20 lbs lean mass gain + 20–30% strength increase

**Stack:**
1. IGF-1 LR3: 50–75 mcg SC, 2x daily post-workout
2. Testosterone (if male): TBD by clinician
3. Sermorelin: 200–300 mcg SC, 3x daily (fasting + pre-bed)
4. Creatine: 5g daily
5. Protein: 1.5–1.8g/lb body weight
6. Carbs: 5–6g/kg body weight
7. Magnesium/Potassium: Optimal electrolytes

**Training:** Hypertrophy block (6–12 reps, 3–4 sets, 3–5x/week)
**Monitoring:** Daily glucose, weekly strength, labs at 4 & 8 weeks

---

### Protocol 2: "Fat Loss + Muscle Preservation" (8-12 weeks)
**Goal:** Lose 1–2 lbs/week fat while maintaining/gaining lean mass

**Stack:**
1. ACE-031: 1–5 mg/kg SC weekly
2. Sermorelin: 200 mcg SC, 2–3x daily
3. Ipamorelin: 100 mcg SC, 2x daily (optional, synergizes with Sermorelin)
4. GLP-1 analog (Cagrilintide): Weekly or as needed
5. Protein: 1.4–1.6g/lb body weight (muscle preservation)
6. Caloric deficit: 300–500 kcal/day
7. Creatine: 5g daily

**Training:** Resistance (3–5x/week) + Zone 2 cardio (2–3x/week, moderate intensity)
**Monitoring:** Weekly body comp, strength maintenance, appetite/GI tolerance

---

### Protocol 3: "GH Axis Optimization" (12–16 weeks)
**Goal:** Restore age-related GH decline, improve recovery, anti-aging

**Stack:**
1. Sermorelin: 200–300 mcg SC, 3x daily (fasting + pre-bed + pre-workout)
2. CJC-1295 (No DAC): 100–200 mcg SC, 2–3x daily
3. Ipamorelin: 100–200 mcg SC, 2–3x daily (synergizes with GHRH)
4. Sleep: 8–9 hours mandatory (GH released during deep sleep)
5. Exercise: Progressive strength training, Zone 2 cardio
6. Magnesium: 400–500mg before bed

**Training:** General fitness (mix of strength, cardio, flexibility)
**Monitoring:** Energy, sleep quality, recovery, body composition monthly

---

## ADMINISTRATION - Monitoring Tools & Safety Protocols

### Glucose Monitoring Checklist (Daily - IGF-1 LR3)
- [ ] Fasting glucose measured (target >80 mg/dL)
- [ ] Post-meal glucose checked (if concerned about spikes)
- [ ] Hypoglycemia symptoms noted: shakiness, sweating, confusion, tachycardia, vision changes
- [ ] Carbohydrate intake logged (minimum 4–6g/kg daily)
- [ ] Water intake logged (minimum 3–4 liters daily)

### Weekly Strength Assessment
- [ ] Squat 1RM or 5RM tested/estimated
- [ ] Bench press 1RM or 5RM tested/estimated
- [ ] Deadlift 1RM or 5RM tested/estimated
- [ ] Progress logged (expect 10–20% improvement over 8 weeks)

### Monthly Body Composition Assessment
- [ ] Weight measured (same time of day, morning preferred)
- [ ] Waist circumference (if not using DEXA/BodPod)
- [ ] Photos taken (front, side, back in consistent lighting)
- [ ] Expected: 1–2 lbs/week gain if hypertrophy protocol

### Lab Submission Schedule
- **Baseline (Week 0):** Fasting glucose, HbA1c, lipid panel, liver/kidney function, testosterone (if male), BP
- **Mid-protocol (Week 4):** Fasting glucose, liver function (if on higher doses)
- **End-protocol (Week 8):** Full repeat of baseline labs
- **Post-cycle (Week 12):** Recovery assessment, lipid panel, hormone levels

### Side Effect Tracking Form
- **Joint pain (1–10 scale):** ___ Location: ___ Limiting activity: Y/N
- **Carpal tunnel severity (1–10):** ___ Numbness: Y/N Tingling: Y/N
- **Glucose incidents:** Hypoglycemic episodes? ___ Frequency: ___ Severity: ___
- **Fluid retention:** Mild / Moderate / Severe
- **Headaches:** Frequency ___ per week, Severity ___ /10
- **Other side effects:** ___

### Contraindication Screening (Must clear before starting)
- [ ] No personal cancer history
- [ ] No family cancer history (or cleared by oncology)
- [ ] Fasting glucose <100 mg/dL
- [ ] Blood pressure <140/90
- [ ] No open growth plates (>25 years old)
- [ ] No severe joint disease or instability
- [ ] Committed to high carb intake (4–6g/kg daily)
- [ ] Access to glucose monitoring (home meter)
- [ ] Willing to do monthly labs

---

## NEXT STEPS
- Document 2: **Repair & Recovery Peptides** (BPC-157, TB-500, GHK-Cu, etc.)
- Document 3: **Metabolic & Weight Loss Peptides** (Cagrilintide, GLP-1 analogs, etc.)
- Document 4: **Bioregulators & Anti-Aging** (Russian bioregulators, Thymosin, etc.)

